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1. ABSTRACT 
Introduction: 
Chronic myeloid leukemia (CML) is a white blood cells cancer, which is characterized by a 
BCR-ABL fusion gene. The disease is caused by a reciprocal translocation between 
chromosome 9 and 22, t(9; 22)(q34; 11) 1 commonly known as the Philadelphia chromosome 
(Ph), resulting in an abnormally BCR-ABL tyrosine kinase, which is responsible for the 
pathogenesis of CML. The high efficacy of the tyrosine kinase inhibitors (TKIs) in the 
treatment of CML has caused the need for sensitive methods to monitor the course of 
therapy. Quantification of BCR-ABL transcripts with qRT-PCR Real-Time has demonstrated 
to be the most accurate method available. 2 Following the European LeukemiaNet 
recommendations, 3 the lack of initial response can be detected only after 3-6 months from 
the diagnosis. The ability to understand how patients respond to the different TKIs available 
as first-line treatment at the moment of diagnosis would help clinicians to prescribe more 
patient-tailored therapy, decreasing the onset of future drug resistance and decreasing 
treatment cost.  
Materials and Methods: 
We have developed and validated two devices (RQ-BCR-ABL p210 One-Step and RQ-BCR-
ABL p190 One-Step) for monitoring therapy of CML. The RQ-BCR-ABL p210 One-Step kit 
has undergone a further external validation in three reference laboratories, belonging to 
LabNet network. 
For what concern the prevision of therapy’s response the University of Verona has 
developed LeukoPredict, an in-vitro device to screen the inhibitory potential of several BCR-
ABL-targeting drugs and to obtain the percentage of inhibition compared to the same non-
treated samples. We took part to this project in the framework of industrial planning, 
performing a Freedom to Operate analysis and a Cost-Effectiveness analysis.  
Results: 
Both kits based in qRT-PCR Real-Time One-Step have showed high reproducibility and high 
sensitivity in quantification of BCR-ABL transcripts, proving to be suitable for CE-IVD mark. 
Moreover, RQ-BCR-ABL p210 One-Step kit has been verified by the LabNet network as a 
suitable device for the monitoring of CML, improving the reproducibility regarding the current 
system used in routine.  
The Freedom to Operate analysis of LeukoPredict has found some close prior patents 
documents, but none could hinder entry into the market. The Cost-Effectiveness analysis 
has demonstrated that LeukoPredict is either cost saving or very cost-effective, depending 
on the scenario analyzed, generating significant savings for health systems. 
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Conclusions: 
This project is able to connect actual principal issues in CML. On one side we have 
developed and validated two devices that completely satisfy actual request of therapeutic 
monitoring in pharmaceutical market making a complete panel to track CML. The develop of 
devices as LeukoPredict helps to decrease the risk of disease’s progression to more 
aggressive phase, personalizing the therapy and obtaining the maximum effectiveness of 
therapeutical choices. This can help physicians in an evidence based decisional therapeutic 
process, avoiding potential conflict of interest and giving a rational explanation to other kind 
of treatment when the risk of failure is too high. Finally, it has been considered as a 
technology that can be affordable and that could contain the cost of healthcare.  
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2. INTRODUCTION 
2.1. CHRONIC MYELOPROLIFERATIVE SYNDROMES 
The term Chronic Myeloproliferative Syndromes refers to certain diseases that originate from 
the neoplastic transformation of the pluripotent stem cell and characterized by clonal 
proliferation of one or more hematopoietic progenitor stem cells in bone marrow and 
extramedullary sites. The proliferation is associated with a relative normal maturation and/or 
differentiation that lead to an increase of granulocytes, red blood cells and/or platelets in 
peripheral blood. Hepatomegaly and splenomegaly are often observed and they can be 
attributed to both the excess of elements in circulating blood and to extramedullary 
hematopoiesis.4 
Biological characteristics, clinical presentations and natural history of the disease can be 
different in each pattern that can however transform from one syndrome to another during 
the course of the disease. Myeloproliferative neoplasms are a heterogeneous group of 
disorders characterized by altered cellular proliferation of one or more hematologic cell lines 
in the bone marrow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Scheme of haemotopoiesis process 
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2.2. CHRONIC MYELOID LEUKEMIA 
Chronic Myeloid Leukemia (CML) represents the most biologically studied chronic 
myeloproliferative syndrome and constitutes a reference model for similar pathologies.  
It is a clonal myeloproliferative disorder, a consequence from the neoplastic transformation 
of the primitive hemopoietic stem cell. The disease is originally monoclonal, involving 
myeloid, monocytic, erythroid, megakaryocytic, B-cell, and occasionally T-cell line-age.5,6 
It is characterized by a constant cytogenetic alteration, called Philadelphia (Ph) 
chromosome. 1,7 It was the first disease in history in which a specific chromosomal 
abnormality was associated to the pathogenesis of the disease. The natural course of the 
CML foresees three phases: chronic phase (CP), accelerated phase (AP) and blastic phase 
(BP). 
CML was probably the first leukemia recognized as a distinct nosological entity. 8 Some of 
the earliest case reports are highly suggestive of CML and date back to 1845. Two patients 
reported massive splenomegaly associated with leukocytosis. Neither of the two cases can 
be related to any of the common diseases known at the time that could give splenomegaly 
such as tuberculosis, already known clinically in the 1840s. 9  
The most important indication of its pathogenesis came a century late. Progress in the 
second half of the 20th century depended critically on the application to leukemia of 
cytogenetics and molecular biology. Advances in chromosome analysis led Nowell and 
Hungerforf in 1960 to the discovery of the cytogenetic abnormality that came to be known as 
the Philadelphia (Ph) chromosome, 10 involving chromosome 22 (Figure 2). In 1973, Rowley 
found out that the Ph chromosome alteration was the result of a translocation involving also 
chromosome 9. This chromosomal alteration was called t(9;22)(q34;q11). 11 Advances in 
molecular biology set the scene for the characterization in the early 1980s of the breakpoint 
cluster region of what was subsequently named the BCR gene, and led rapidly to the 
identification of the BCR-ABL fusion gene. 12 Researchers in the 1990s provided convincing 
evidence that this fusion gene really was the “initiating event” in the chronic phase of CML.  
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Figure 2. Detail from Nowell and Hungerford's paper in 1960 identifying 
the Philadelphia chromosome. (From the Journal of the National Cancer 
Institute) 
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2.2.1. EPIDEMIOLOGY 
Although knowledge about clinical and molecular characteristics of chronic myeloid leukemia 
(CML) has increased, reliable epidemiological information on CML is limited.13 
CML is relatively rare. CML is more common in older adults and amongst men. The number 
of new cases of chronic myeloid leukemia was 1.8 per 100000 people every year, and with a 
median age at diagnosis of around 64 years.14 
  
        
 
 
 
 
 
 
 
 
 
 
 
 
Disease incidence appears to be consistent across geography and ethnicity, although it is 
noted that survival rates in some countries are likely to be impacted by the availability of 
drugs and diagnostic technologies. 14 The increasing prevalence rate was mainly due to the 
use of TKIs therapy positively influencing survival and life expectancy of CML patients.15 
 
  
Figure 3. Percent of New Cases by Age Group. (From SEER, all 
races, both sexes) 
Figure 4. Number of New Cases per 100,000 Persons by Race/Ethnicity 
& Sex (From SEER, Age-Adjusted) 
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2.2.2. PHYSIOPATHOLOGY 
CML phases 
Chronic phase 
Chronic phase is the initial phase, if untreated, has a median duration of 3.5-5 years before 
evolving to a blastic phase, sometimes preceded by an intermediate or accelerated phase.  
At this phase the disease is frequently asymptomatic. 16 Whenever the symptoms occur, the 
patients present a gradual onset of fatigue, weight loss, increasing sweating, anorexia, early 
satiety and left upper quadrant pain because of splenic enlargement.17 
At this stage, there is a substantial increase in myeloid precursors and mature cells that 
reach prematurely blood flow, but are still able to differentiate.  
 
Accelerated phase 
This phase is characterized by an increase of blasts in peripheral blood (around 15%) and is 
often associated with variable degree of bone marrow fibrosis. In about 70% of CML cases, 
the accelerated phase evolves naturally in the blast crisis.18 
Sometimes the accelerated phase may go unnoticed, in consequence of the absence of 
obvious clinical and laboratory signs and the shortness of the phase, so normally the chronic 
phase seems to evolve directly to the blastic phase. In the clinical practice it is not simple to 
identify the three phases of the disease, probably linked to the time of diagnosis, the therapy 
or the follow up.  
 
Blast phase 
This phase is also defined as ‘terminal phase’ or ‘aggressive phase’. 4 The progressive 
stoppage of maturation and/or differentiation leads to an increase in peripheral and 
medullary blasts. Blast infiltration pattern mediates anemia and thrombocytopenia, 
increasingly accentuated by the course of this phase.  
It is defined as a percentage of blasts greater than 30% detected in peripheral blood and/or 
in the marrow, or extramedullary disease.19 
In this phase, additional chromosomal alterations of cases like trisomy 8, isocromosome 17, 
t(3;21)(q26;q22) are described in 50-80% cases.20 
The duration of the blast crisis is short, it usually covers about 6 months and ends in 90% of 
the cases with the patient’s death. While following therapy, reconversion of the blast crisis in 
the chronic phase is observed in some cases (10-30%) and especially in lymphoid blast-like 
crisis (40-70%).  
 
The definitions of the CML’s phases that are identified by European LeukemiaNet (ELN) 3 
are not the same as those identified by the World Health Organization (WHO) 21 Table 1, but 
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are the ones that have been used globally, and applied in almost all recent and relevant 
studies of CML.  
  
 
  
Accelerated 
phase 
Definition 
ELN criteria 
Blast in blood or marrow 15-29%, or blasts lus promyelocytes in blood or 
marrow >30%, with blasts <30% 
Basophils in blood ≥20% 
Persistent thrombocytopenia (<100 x 109/L) unrelated to therapy 
Clonal chromosome abnormalities in Ph+ cells (CCA/Ph+), major route, 
on treatment 
 
 
WHO criteria 
Blasts in blood or marrow 10-19% 
Basophils in blood ≥20% 
 
 
Persistent thrombocytopenia (<100 x 109/L) unresponsive to therapy 
Increasing spleen size and increasing white blood cell count 
unresponsive to therapy 
Blast phase  
ELN criteria 
Blasts in blood or marrow ≥30% 
Extramedullary blast proliferation, apart from spleen 
 
 
WHO criteria 
Blasts in blood or marrow ≥20% 
 
 
Extramedullary blast proliferation, apart from spleen 
Large foci or clusters of blasts in the bone marrow biopsy 
Table 1. List of the criteria for the definition of AP and BP, as recommended by ELN3,22 and 
by the World Health Organization21 
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2.2.3. ETIOPHATOLOGY  
CML is characterized by the presence of the Philadelphia chromosome.11 
For many years, the Philadelphia chromosome has been the only known cytogenetic 
abnormality related to a specific human malignant disease. This chromosome is made from 
reciprocal translocation of genetic material between chromosomes 9 and 22, reported as 
t(9,22)(q34;q11). 11 The result is that a fusion gene is created by juxtaposing the 3’-end of a 
strand of ABL1 (Abelson) gene on chromosome 9 to a 5’-end of a strand part of the BCR 
(breakpoint cluster region) gene that stays on chromosome 22. Translocation results in an 
oncogenic BCR-ABL gene fusion. 
The Ph chromosome is present in more than 95% of cases of CML. It also found in 5% of 
Acute Lymphoblastic Leukemia (ALL) cases in children, 10-25% of ALL cases in adults and 
2% of Acute Myeloid Leukemia (AML). For ALL and CML presence of this translocation is a 
marker for a negative prognosis.23 
In cases where the Philadelphia chromosome is not observed through conventional 
cytogenetic analysis, BCR-ABL translocation can be detected using FISH and/or molecular 
biology techniques. In these cases so-called CML Ph-negative (Ph-masked) more complex 
mechanisms can occur, such as the insertion of BCR-ABL arrangement from chromosome 
22 to chromosome 9, successively to the initial t(9;22). 24 As a consequence of these 
mechanisms the alteration is not visible with conventional cytogenetic methods. 
 
2.2.3.1. The physiologic function of the translocation partners 
In order to understand the mechanisms through which the BCR-ABL oncogene plays a 
leading role in the pathogenesis of CML, and therefore the consequential formation of 
proteins, it is important to analyze the biological function of genes involved in translocation 
t(9;22): ABL and BCR.25 
ABL gene 
ABL is a tyrosine-kinase protein (TKP). TKPs regulate a multiple cellular processes, 
including cell growth, differentiation, migration and apoptosis. Their activity is normally 
closely controlled and regulated. Perturbation of TKPs signalling by mutations or other 
genetic alterations results in deregulated kinase activity and malignant transformation.26 
ABL gene encodes a nonreceptor tyrosine kinase. 27 It is a 145-kd protein (p145), 
ubiquitously expressed. This protein presents two isoforms (type 1a or 1b) that originate 
from an alternative splicing in the first exon. 27 This protein has been well studied, identifying 
different structural domains within it (Figure 5).  
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The p145 contains: - one of the N-terminal domains encoded respectively by exon 1a or 1b; - three SRC-homology (SH1-SH3) near to the N-terminal. The SH1 domain possesses 
the tyrosine kinase function, while the SH2 and SH3 domains allow interaction with 
other proteins;28 - proline-rich sequences (PPs) in the center of the molecule, which may interact with 
SH3 domains of other proteins, like a Crk;29 
Toward the 3’ end the following are found: - nuclear localization signals (NLS);30 - one nuclear exporting  signal (NES); - a DNA-binding domain (DBD);31 - an actin-binding domain (ABD); 32  this actin-binding domain contains binding sites for 
both monomeric (G) and filamentous (F) forms of actin. 
 
 
 
Thereby, the ABL protein is implicated in several cellular processes, such a regulation of the 
cell cycle, 31,33 the cellular response to genotoxic stress, 34 and in the transmission of 
information about the cellular environment through integrin systems.35 
 
BCR gene 
BCR gene encodes for a 160-kb protein (p160). As with ABL, it is ubiquitously expressed.27 
The 160-kDa protein has different domains (Figure 6): - the first N-terminal exon encodes a serine/threonine (S/T) kinase; - a coiled-coil (CC) oligomerization domain;36 - a Dbl/CDC24 guanine-nucleotide exchange factor homology (DH) domain and a 
pleckstrin homology (PH) domain in the center of the molecule, that activate the 
exchange of guanidine triphosphate (GTP) for guanidine diphosphate (GDP);37 - a putative calcium-dependent lipid binding site (CaLB); 
Figure 5. ABL gene structure. 
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- and a RAC guanosine (p21rac) 38 triphosphatase-activating protein (RAC-GAP) 
domain.39 
 
 
Moreover, BCR can be phosphorylated on many tyrosine residues, 40 particularly tyrosine 
177, which interacts with Grb-2, an essential molecule implicated in the activation of the Ras 
pathway. 41 The true biologic relevance of BCR is still unknown.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6. BCR gene structure 
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2.2.3.2. Molecular anatomy of the BCR-ABL translocation 
Breakpoints within the ABL gene may occur anywhere in the 300kb area of the 5’ ends, 
either before the first alternative exon 1b, after the second alternative exon 1a or, as it more 
frequently occurs, between the two. 23  
In BCR gene, however, breakpoints occur in 1 of 3 so-called Breakpoint Cluster Regions 
(BCR), resulting formation of at least three different fusion genes coding proteins with 
different molecular weight. These proteins turn out to be associated with three different types 
of leukemia (Figure 7):42 
• P190: chromosomal breakpoint on ch 22 between exons e1-e2 (Minor Breakpoint 
Cluster region, m-bcr) associated to 20-30% of acute lymphoblastic leukemias (ALL). 
• P210: breakpoint between exons b1-b5 (Major Breakpoint Cluster region, M-bcr, 
almost 5.8 Kb) associated to 90% of CML. 
• P230: breakpoint between exons e19-e20 (centromere breakpoint zone compared to 
M-bcr) associated to a subgroup of patients with chronic neutrophilic leukemia (CNL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although the e1-a2 transcript (that encodes for the p190BCR-ABL) was primarily associated 
with ALL, cases characterized exclusively by this type of transcript have been described in 
sporadic CML, with the exclusive production of p190BCR-ABL protein. These types of patients 
Figure 7. Translocation t(9,22)(q34;11) and structure of the chimeric mRNAs derived from the 
various breakpoints. 
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are associated with a worse outcome with the tyrosine kinase inhibitors (TKIs) therapy, and 
must be identified as a high-risk group. 43 Moreover, it has been verified that most of CML 
patients express at the diagnosis not only the typical p210BCR-ABL transcript, but also low 
levels of e1-a2 transcript (through an alternative splicing mechanism).44 
It should be noted that the ABL part of the chimeric protein is almost invariable, whereas the 
portion of BCR varies considerably. It can be deduced that it is the portion of ABL that 
probably carries the principle of malignant transformation, whereas the different sizes of the 
BCR sequences may determine the disease phenotype.42 
It is unclear whether differences in the activities of the three proteins make it possible to 
associate them with different phenotypes of the disease or whether the expression of each 
protein occurs in a distinct hematopoietic line. 23 It has been shown that larger size of the 
BCR portion in the fusion protein is related to a decrease in tyrosinkinase activity of ABL: 
consequently, p230 shows lower tyrosinkinase activity than p210 and p190, and in turn p210 
has less activity than p190. 45-47  
The specific cause of chromosome translocation is unknown today. One of the proposed 
hypotheses foresees the presence of fragile sites in correspondence with the breakpoints in 
the interested DNA region.48 
However, according to another hypothesis, 49 the proximity of the ABL and BCR genes could 
favor illegitimate recombination because of the spatial distribution of chromosomes 9 and 22 
before the metaphase, could favor illegitimate recombination. Nevertheless, analysis of the 
flanking sequences at the breakpoints has not revealed the presence of repeated sequences 
that could favor translocations. 
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2.2.3.3. Mechanisms of BCR-ABL mediated malignant transformation 
BCR-ABL oncogene formation leads to a structural alteration of some of the regulatory 
domains of the normal ABL and BCR proteins: - The tyrosin-kinase activity of ABL, usually present at the nuclear level, is 
predominantly transferred to the cytoplasm and is constitutively activated, either 
because of the loss of the inhibitory action of SH3 domain, 50 or through 
oligomerization of the N-terminal domain of BCR, with consequent 
autophosphorylation in multiple sites; - The spatial configuration of some BCR domains is modified, making them available 
to bond with proteins that activate different signal transduction pathways;42 
These alterations give Ph-positive cells a high tyrosin-kinase activity, which plays a central 
role in the leukogenesis process.  
BCR-ABL induces the progression of the disease through 4 principal mechanisms (Figure 8): 
1. Altered adhesion properties 
By modifying the adhesive properties to bone marrow stroma cells and to 
extracellular matrixes, increasing the rate at which they are released into peripheral 
blood and to the extracellular matrix. 51,52 Ph-positive cells exhibit a dysregulation of 
signal transduction mediated by the integrin system and are characterized by the 
hyperphosphorylation of Crkl53 a protein involved in cellular motility and cell adhesion 
through association with other factors including paxilin;54 
2. Activation of mitogenic signalling 
By causing the activation of mitogenic signals. 42 The involvement of the JAK-STAT 
pathway had been demonstrated by studies in v-Abl-transformed B cells. 55 The RAS 
system is involved either directly by its phosphorylation, or indirectly by the 
phosphorylation of intermediate substrate (Shc, Crkl). 53,56 The involvement of the 
JAK-STAT system has been demonstrated in numerous Ph-positive cell lines57 and 
in primary CML cells. 58 The two systems, RAS and JAK-STAT, make the BCR-ABL a 
number of growth factor-dependent cell lines factor independent. 59,60On the other 
hand, PI3 kinase activity, like a Myc pathway, contributing for the proliferation 
activity.61,62  
3. Inhibition of apoptosis 
By inhibiting apoptosis by activating some signal transduction pathways such RAS, 
63,64 and involving several proteins like Bcl-2. 65 In particular, CML cells express a 
number of anti-apoptotic molecules that can contribute to the growth in survival rates 
of leukemic cells, such as the Bcl-2 family of proteins. The role and effects of Bcl-2 
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and other anti-apoptotic molecules may depend on the presence of endogenous 
inhibitors and antagonists expressed in leukemic cells, one of which is represented 
by the Bim protein. 66 The members of the Bcl-2 family act by regulating the 
translocation of cytochrome C from the mitochondria to the cytosol, an event that 
activated the caspase cascade. 67,68 Physiologically, Bim levels are regulated by 
cytokines such as IL-3, while phosphorylation and subsequent degradation of Bim by 
BCR-ABL is one of the major mechanisms through which leukemia cells become 
resistant to apoptosis.66 
 
4. Degradation of inhibitory proteins. 
A recent study shows that BCR-ABL induces the proteasome-mediated degradation 
of Abi-1 and Abi-2, two with inhibitory function, may be the first indication of yet 
another way by which BCR-ABL induces cellular transformation. 69  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8. Signaling pathways activated in BCR-ABL positive cells. 
 16 
2.2.4. MONITORING OF CHRONIC MYELOID LEUKEMIA 
The detection of BCR-ABL positivity is crucial for the genotyping of the disease. Monitoring 
of the amount of BCR-ABL transcripts gained relevance for the assessment of treatment 
efficacy. An early reduction of transcript levels has been shown to be a prognostic factor in 
CML, predicting cytogenetic response and clinical outcome in treated patients with tyrosine 
kinase inhibitors (TKIs).70-72 
In addition, the degree of molecular response correlated with progression-free survival (PFS) 
and event-free survival (EFS) in these patients. 73 For patients submitted to stem cell 
transplantation (SCT) reappearance or persistence of BCR-ABL transcripts indicates an 
increased risk of relapse. 74,75 Warning signs are given due to rising transcripts levels with a 
loss of Major Molecular Response (MMR, defined as BCR-ABL expression ≤ 0.1 according 
to the International Scale, explained in more detail below) as well a serial increase of 
transcript levels. 3 In cases in which patients do not get quickly significant reduction of 
transcript levels, a lower probability of achieving a MMR and higher risk of disease 
progression exists. 76,77  
ELN (European LeukemiaNet) and NCCN (National Comprehensive Cancer Network) 
recommend monitoring the treatment through hematologic, cytogenetic, and molecular tests, 
every 3-6 months from the start of therapy, in order to identify and optimize treatment for that 
minority of respondents who respond more slowly. 3,78 PCR-based tests are considered the 
“gold standard” methods for molecular monitoring, through the detection and quantification of 
BCR-ABL transcripts, since they show a high sensitivity  (up to 0.001%). 
Molecular response (MR) is measured through the fraction of the total amount of BCR-ABL 
transcript divided by the total amount of the housekeeping control gene.  𝐵𝐶𝑅 − 𝐴𝐵𝐿𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑒𝑛𝑒  𝑥 100 
There are different levels of MR (Figure 9): - MR3 (≥3-log reduction from IRIS baseline) = Detectable disease ≤0.1% BCR-
ABLIS or absence of BCR-ABL transcripts in cDNA with 1000-10000 ABL transcripts. - MR4 (≥4-log reduction from IRIS baseline) = Detectable disease ≤0,01% BCR-
ABLIS or absence of BCR-ABL transcripts in cDNA with 10000-31999 ABL 
transcripts. - MR4.5 (≥4.5-log reduction from IRIS baseline) = Detectable disease ≤0.0032% 
BCR-ABLIS or absence of BCR-ABL transcripts in cDNA with 32000-99999 ABL 
transcripts. 
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- MR5 (≥5-log reduction from IRIS baseline) = Detectable disease ≤0.001% BCR-
ABLIS or absence of BCR-ABL transcripts in cDNA with ≥100000 ABL transcripts. 
 
 -  
 
 
 
 
 
 
 
Major Molecular Response (MMR) 
A key indicator of molecular response is Major Molecular Response (MMR), the reduction of 
≥ 3 logarithms in the amount of BCR-ABL transcripts over a standardized baseline. This 
baseline is determined in the IRIS study for untreated patients.79 
 
Achieving MMR is strongly associated with an increased probability of long-term stable 
molecular response, and better progression-free survival (PFS) in patients receiving 
TKIs.73,80-82 
 
Despite the proven prognostic value of MMR, a wide variation in the methods used to 
quantify BCR-ABL transcripts and the lack of universally accepted standards have led to 
significant variations in results, making comparisons between laboratories difficult. 
Therefore, a harmonization of BCR-ABL measurement is required for optimal clinical 
management. Thus, it will be possible to compare and group results from different 
laboratories and study groups.  
 
Bearing in mind the clinical importance of MR evaluation, methods have been developed to 
harmonize the results of BCR-ABL quantification worldwide. Perhaps, one of the most 
important steps towards this standardization was the creation of the International Scale (IS) 
in 2005. 83 This International Scale has two standard values: an initial baseline value of 
Figure 9. Scheme of different levels of Molecular Response  
(From Baccarani, M., & Soverini, S. (2014) Blood, 124(4), 469-471). 
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100%IS (as determined in the IRIS study for untreated patients), 79 and the value of 0.1%IS 
which corresponds to the MMR point (3 log reduction from the initial baseline). 
 
 
 
 
 
 
 
 
 
 
The only mechanism currently available, by which laboratories can adopt the IS for their 
results is to establish a laboratory-specific conversion factor (CF). The CF is obtained by 
quantifying a certified reference material with its own method. 84 
The different laboratories can continue to use their routine system for BCR-ABL 
measurements, and generate comparable results with their historical data. With the CF 
application, this data can be converted to IS, making it directly traceable with the IRIS scale 
(Figure 10). In this way, the results of different center can be compared to each other.   
In Italy it is the LabNet network that monitor this standardization. To date, 120 haematology 
centers and 56 laboratories have been standardized and are subject to quality controls. 
 
Control Gene 
The election of an adequate control gene is decisive for the success of molecular response 
monitoring. Choosing an appropriate control gene is crucial in order to have reliable data that 
can be reproduced. Comparison of the results obtained for the control gene helps in the 
identification of unsuitable RNA samples.  85-87  
Using an appropriate control gene is important for several reasons:85,88-90 
- To compensate for variations in transcription levels that may occur due to sample 
Figure 10. The international Scale (IS) for BCR-ABL real-time 
quantitative measurements. (From Müller, M. C., et al. Leukemia 
23.11 (2009): 1957-1963.) 
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degradation after collection; - To regulate the differences in the efficiency of the inverse transcription phase and the 
variations in the final amount of RNA; - To help to evaluate the sensitivity of each sample measurement. 
The control gene must fulfil the three following criteria: 
1. It should have an expression level broadly similar to that of BCR-ABL at diagnosis of 
CML; 
2. It should have stability similar to BCR-ABL; 
3. Primers for the gene should be proven not to amplify sequences from genomic DNA 
such a pseudogenes. 
Similar levels of RNA stability are essential since delays in sample processing are common 
and substantial changes in expression can occur very rapidly after blood collection. 90,91  
The most appropiate and frequently used three control genes for BCR-ABL quantification are 
BCR, ABL and β-glucuronidase (GUSB). Currently, the most used is ABL, although BCR 
and GUSB are equally suitable. 89  
 
2.2.4.1. Test Principle 
The PCR method (Polymerase Chain Reaction) was the first method of DNA amplification 
described in literature. 92 It is a method for in vitro amplification of a specific part of DNA 
(target sequence) by use of a thermostable DNA polymerase. This technique was shown to 
be a valuable and versatile instrument of molecular biology: its application contributed to a 
more efficient study of new genes and their expression and has revolutionized for instance 
the fields of laboratory diagnostics and forensic medicine. 
The Real-Time PCR represents an advancement of this basic research technology, 
providing the possibility to determine the number of amplified DNA molecules (amplicons) 
during the polymerase chain reaction (PCR). 
In the system at hand, monitoring the amplification progress is based on primers/probes 
labeled with fluorescent molecules. These probes contain a reporter fluorophore and a 
molecule (quencher) that blocks the reporter’s specific fluorescence. Its distance to the 
quencher determines the fluorescent emission of the reporter. As long as a probe is not 
bound to a target sequence, the reporter and quencher are in close proximity and the 
reporter’s fluorescence is blocked. Upon binding to a target sequence, quencher and 
reporter become separated and the reporter can emit fluorescent light, which is detected. 
Typically, the main part of a Real-Time PCR run consists of 30 to 50 amplification cycles. A 
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thermocycler equipped with an adequate detector can record the fluorescence events at 
each cycle and thus monitor the reaction in “real time”. The cycle at which the fluorescence 
of the amplification product becomes clearly distinguishable from the background is specific 
for each reaction and is correlated to the initial concentration of the target sequence. This 
cycle is called threshold cycle (Ct). The Ct value is used to determine the initial target 
concentration, with the help of a standard curve. A standard curve is created by amplification 
of solutions with known concentrations of the target sequence (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
The main advantage of the Real Time PCR compared to conventional techniques of 
amplification is the possibility to perform a semi-automated amplification, generating not only 
qualitative data but also quantitative data. This means, the extra steps necessary to visualize 
the amplification result are be avoided and the risk of contamination by post-PCR 
manipulation is reduced. 
 
 
 
  
Figure 11. Creating a standard curve using points with 
known concentrations 
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2.2.5.  CHRONIC MYELOID LEUKEMIA THERAPY 
The treatment of CML patients has undergone a great evolution in a relative short period of 
time. Initially, several treatments were tried in the hope of improving CML prognosis (arsenic, 
splenectomy, splenic irradiation, busulfan) without achieving good results. In 1963, 
hydroxyurea, a ribonucleotide reductase inhibitor was developed, and immediately 
afterwards it was tested in CML therapy93 Hydroxyurea remains useful for short periods 
before tyrosine kinase inhibitors (TKIs) treatment, until confirmation of CML diagnosis. 3 The 
first therapy capable of inducing a considerable cytogenetic remission was interferon-alpha 
(IFN-α), today used only in rare cases where TKIs cannot be used. The combination IFN- α 
with TKIs seems to be potentially efficient, but is still in an experimental phase.94 
Recently, CML therapy has radically improved with the introduction of tyrosine kinase 
inhibitors.95 
2.2.5.1. Definition of the response 
In each patient the response to therapy will be evaluated over time. European LeukemiaNet 
(ELN) distinguishes three grades of response. These definitions are clinically important 
because they provide a guide to therapy (Table 2). The response to treatment may be 
defined as “optimal”, “failed” or “warning”, according to ELN. 3  
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Definition of the response to TKIs (any TKI) as first-line treatment 
(From Baccarani, Michele, et al. Blood 122.6 (2013): 872-884.) 
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2.2.5.2. First Generation of Tyrosine Kinase Inhibitor 
IMATINIB 
Since 1999, CML therapy has undergone profound changes with the introduction of the first 
TKI, Imatinib (STI571 or Gleevec®/Glivec®), an antineoplastic agent developed with the aim 
of selectively inhibiting certain tyrosine kinases involved in oncogenesis. This became the 
first example of targeted therapy, as it targets and attacks the causative agent of CML. 
Imatinib is a 2-phenylamina pyrimidine class96,97 (to which ABL tyrosine kinase belongs) and 
was created using the kinase ATP binding site structure (Figure 12)98 
 
 
 
 
 
 
It was initially developed as a specific inhibitor of the platelet-derived growth factor (PDGF) 
signal transduction pathway, but was later discovered to inhibit the autophosphorylation of 
several tyrosine-kinase such v-Abl, c-Kit, and to block PDGF-induced inositol phosphate 
formation.97,99Additional analyses revealed that Imatinib binds to the inactive form of BCR-
ABL on the normal ATP-binding site, thus preventing interaction with ATP and switching to 
active form (Figure 13).100 
 
 
 
 
 
  
Figure 12. Imatinib (Glivec®, Novartis) 
Figure 13. Imatinib interaction with tyrosine-kinase proteins 
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This results in a block of both the ability of BCR-ABL to autophosphorylation and its ability to 
phosphorylate other target proteins, essential to conferring and maintaining the Ph-positive 
leukemia phenotype, 96,97 thus inhibiting proliferation and inducing cellular apoptosis98,101 
(Figure 14). 
 
 
 
 
 
 
 
 
 
In 1998 Imatinib was introduced for clinical investigation and in 2001 was approved by FDA 
(Food and Drug Administration) and EMA (European Medicines Agency) for CML patients 
who had unsuccessful treatment with IFN. 102-105 In December 2002, treatment of patients 
with newly diagnosed CML (first-line treatment) was approved. 106 Since 2016, 
Novartis’composition of matter Imatinib was expire. The impact on health system spending 
levels for CML after generic Imatinib has become available is the subject of considerable 
interest among stakeholder including physicians, payers, and patients. 
Recently the first-line therapy with Imatinib have been reported in many studies. 73,79,81,107-125 
49% to 77% of the patients who used 400 mg of Imatinib daily for 1 year achieved the 
complete cytogenetic response (CCyR), and 18% to 58% achieved the major molecular 
response (MMR). 111,112,114,121,125 Instead, using 600 mg or 800 mg the CCyR was achieved 
from 63 to 88% of the patients and from 43% to 47% for what concerns the MMR. 
For high risk patient, 73,107,112,121-125 the CCyR at 1 year ranged from 48% to 64%, whereas 
the MMR ranged from 16% to 40%. 
The progression-free survival (PFS), at least at 5 years of follow-up, was described growing 
Figure 14. Imatinib mechanism of action 
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from 83% to 94%; the overall survival (OS) ranged between 83% and 97%. The patients still 
receiving Imatinib as initial treatment was reported at 63% to 79% after 3 to 5 years, and 
after 8 years only the 50%.2,83,113,118,120 More than 800 mg daily was reported in one study. 118 
To date no clinically relevant late onset side effect are described.   
The selective inhibition of BCR-ABL by Imatinib has substantially changed the therapy and 
the natural history of the disease. However, despite the high percentage of hematologic and 
cytogenetic responses, resistance to treatment may develop in a portion of patients. In 
addition, there is a minority of patients who are intolerant to treatment. The resistance to 
Imatinib can be hematologic, cytogenetic and molecular. This resistance comprises the 
inability of the drug to induce a normalization of haematological values or to reduce the 
share of BCR-ABL transcripts.   
Molecular resistance to treatment often occurs due to the existence of mutation in the kinase 
domain. Some of the mutations to the kinase domain reported so far have a detrimental 
effect on the affinity and efficacy of TKIs. 126 The mechanism by which some mutations 
disrupt the binding affinity has been studied. One of the mutations, T315I, substitutes a 
threonine with an isoleucine. The substitution between these two amino acids removes an 
important H-bond donor from the ATP binding site. To date, the result of this mutation yields 
one of the most resilient mutations to TKIs known. 127   
Several mutation points have been shown to be related with an increase of resistance to 
TKIs (Figure	15), thus showing how the region in which the mutation happens is a possible 
predictor of the clinical outcome.128 
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New molecules and Imatinib analogs were developed to avoid resistance, giving rise to the 
second and third generation of TKIs.  
Figure	15.	Scheme	of	the	activity	of	TKIs	against	a	selection	of	BCR-ABL1	mutants	
found	in	patients	with	CML.	The	concentrations	are	shown	in	nM/mL	and	represent	
IC50	values	(from	Quintàs-Cardama,	Blood	113	2009) 
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2.2.5.3. Second Generation of Tyrosine Kinase Inhibitors 
As stated above, a percentage of patients treated with Imatinib result resistant or intolerant 
to it. The resistance is due to mutations points in the kinase domain of the ABL portion in 70-
90% of cases. These mutations are involved specifically in residues implicated in binding to 
Imatinib or, more frequently, residues important for BCR-ABL’s ability to adopt a 
conformation favorable to binding Imatinib. 126,127,129-131 Based on this, new drugs have been 
developed: Nilotinib and Dasatinib. 
 
NILOTINIB 
 
 
 
 
 
The binding of Nilotinib (Figure 16) to BCR-ABL is more favorable than the same bond with 
Imatinib. This results in a more selective action of Nilotinib on target cells. In fact, it has been 
demonstrated that Nilotinib has shown a 30-fold higher potency than Imatinib in vitro. 123 This 
feature is particularly important for older patients, because they tend to have more difficult 
tolerating treatment with Imatinib, especially if used in high doses. 
The efficacy of Nilotinib in patients with Imatinib resistance has been demonstrated in 
several phase 2 trials applying a dosage of 400 mg twice daily. 132-134 In 2007, Nilotinib was 
approved for second-line treatment in blast phase and accelerated phase.  
 
Today, Nilotinib can be used as a first-line treatment, 3 with significantly higher and faster 
rates of MMR and CCyR and lower progression rates compared with Imatinib.121 
Furthermore, it has been shown that Nilotinib has pro-apoptotic properties resulting in an 
increase in Bim protein levels and thus acting as an oncosuppressor in leukemic cells. 
Because the BCR-ABL acts by degrading Bim and thus inhibiting the apoptotic process, 
Nilotinib inhibiting BCR-ABL activity, acts as antagonist.135 
  
Figure 16. Nilotinib (Tasigna®, Novartis) 
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DASATINIB 
Dasatinib (Figure 17) is a dual specific ABL and SRC gene kinase inhibitor, not structurally 
related with Imatinib. Dasatinib has demonstrated 325-fold higher potency than Imatinib in 
vitro, for unmuted BCR-ABL. 136 Dasatinib is able to inhibit other tyrosine kinases such SFK, 
c-kit and PDGFR-beta. SFK has an important role in the progression to blastic phase, thus a 
part of the therapeutic effect of Dasatinib might be related to inhibition of SFK.  137-139  
Many phase II trials in patients with resistance or intolerance to Imatinib demonstrated proof 
of efficacy within the START program (SRC/ABL Tyrosine Kinase Inhibition Activity: 
Research Trials of Dasatinib).140-146 
 
 
 
 
 
 
Dasatinib was approved in 2006 for the treatment of patients with resistance or intolerance 
to Imatinib. 147 A high efficacy as first-line therapy for CP has been proven. A comparative 
study that investigated Dasatinib 100 mg daily versus Imatinib 400 mg daily as first-line 
therapy, demonstrated higher and faster rates of CCyR and MMR after one year. 124 
The European LeukemiaNet (ELN) recommendations indicate that patients with new 
diagnosis of CML should be treated with Imatinib, Nilotinib or Dasatinib, and have a follow-
up to identify the success or failure of therapy. 3 Even though it is known that Nilotinib and 
Dasatinib are more powerful and induce deeper and faster remissions and lower risks of 
accelerated phase/blast phase (AP/BP) transformation, there is not yet concrete proof of a 
better outcome, if a second-generation TKI is used first-line. 123,125 Second generation of 
TKIs are frequently preferred in patients with a high score in the Sokal148 o Hasford149 scale, 
or when the priority is to rapidly reach deep Molecular Responses (MRs). 150 However, the 
long-term safety profile of these drugs remains unclear to date. Even though serious adverse 
effects (AE) such as pulmonary toxicities151,152 or vascular disease153,154 occur infrequently 
with second-generation TKIs, these AEs lead to significant morbidity when they occur. 
Figure 17. Dasatinib (Sprycel®, Bristol-Myers Squibb) 
 28 
Despite the clear differences in AP/BP transformation rates, these AEs contribute to the lack 
of significant difference in overall survive rates (OS) between patients treated with Imatinib 
and those receiving Nilotinib or Dasatinib. 123,125  
In general, for most patients, the current treatment for CML is rendering it more of a chronic 
disease with a high median survival rate. 155 Quality of life issues require more attention 
since the overall survival of most patients has improved.  
2.2.5.4. Stem Cell Transplantation 
After the introduction of TKIs treatment the percentage of allogeneic Stem Cell 
Transplantation (SCT), the only treatment that can currently render patients molecularly 
negative, has significantly decreased. The associated procedural-related morbidity and 
mortality remain a major brake.  156 Indications for allogeneic SCT in fit patients below the 
age of 65 are today:157 
i. A significative progression to advanced phases; 
ii. Failure of first- or second-generation TKI treatment; 
iii. Appearance of the T315I mutation with failure of TKI treatment; 
iv. Patient’s willingness. 
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2.2.6.  PREDICTION OF THERAPEUTIC RESPONSE 
To date there still are issues that remain pending regarding the long-term safety profile of 
these drugs. Although severe adverse effects, such as cardiovascular or pulmonary, do not 
commonly occur with 2nd generation of tyrosine kinase inhibitors (TKIs), when they appear 
they lead to a worse morbidity. This toxicity could partly contribute to the lack of significant 
overall survive differences among patients treated with Imatinib and those treated with 
Nilotinib or Dasatinib, despite the differences in the acute phase/blastic crisis transformation 
rate158. 
Approximately 1/3 of patients treated with Imatinib at first line and about 1/10 of those 
treated with Nilotinib and Dasatinib do not get early molecular response (EMR). The failure 
of early molecular response is not predictable on the basis of clinical features, so the 
identification of biological parameters that can define the response to treatment would be of 
great interest and clinical significance. 
The European LeukemiaNet recommendations have considered that a single molecular test 
of BCR-ABL transcript quantification cannot be sufficient to take such an important decision 
as the change of treatment. At least two tests are required, at 3 and 6 months (Table 2), to 
provide a sounder basis for treatment decisions.3 
The existence of several first-line therapeutic options and the inability to predict each 
individual response slow down the therapeutic course, not allowing full use of the potential 
for therapeutic efficacy due to the availability of more first-line therapeutic options. 
As already mentioned there are several methods for CML diagnosis and monitoring. 
However, these analyses do not provide information on how drugs could work on patients in 
terms of efficacy and bioavailability. 
Several factors may give some indication of TKIs response and outcome. There are three 
prognosis systems –Sokal148, Euro149, and EUTOS159- based on clinical and haematological 
data that have been shown to be still useful160 (Table 3).  
 
Table 3. Calculation of the risk related to obtaing a poorer response to TKIs (From Baccarani, Michele, et al. Blood 122.6 
(2013): 872-884.) 
	
	
	
 30 
To date, there is no evidence of which of the three prognosis system is superior or more 
convenient and there is no clear evidence that patients with intermediate risk behave 
differently than low-risk patients. 
 
Prognostic implications of some basic factors such as gene expression profiles, the 
polymorphism of genes encoding TKI transmembrane transporter, TKI-mediated apoptosis, 
and detailed molecular dissection of the genome have been demonstrated. However, these 
data are not yet sufficiently mature to be used for treatment planning3. 
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Figure 18. Schematic of the tyrosine kinase assay based on phospho-peptide. On the left the peptide bound 
to a solid phase is shown. After addition of specific kinase the phosphorylation that occurs between the 
interaction kinase-peptide can be detected using antibodies coupled with horseradish peroxidase (HRP) or 
other appropriate reporters.162,163  
2.2.6.1. Tyrosine Kinase Assay 
Tyrosine-kinase assays are well-established instrument in the modern biochemistry. In the 
last few decades, the importance of cell phosphorylation events has been increasingly 
recognized, based on the knowledge of the fundamental role of kinase proteins in all aspects 
of cellular physiology such as growth, differentiation, and metabolism161. Using HTS (High 
Throughput Screening) technology, new drugs have been developed that work as kinase 
enzymatic modulators in a wide range of diseases such as neoplasms, inflammatory 
diseases, neurological disorders, and metabolic disorders.162,163 
The classification of the different kinase assays includes: 
- Detection of the phospho-peptide 
- ATP consumption 
- Analysis of ADP production 
 
 
 
 
          
 
 
2.2.6.2. LeukoPredict™ 
LeukoPredict screens in vitro the inhibitory potential of several BCR-ABL-targeting drugs 
simultaneously and obtain the percentage of inhibition compared to the same non-treated 
samples. This system indicates the most effective first-line treatment before therapy 
initiation. It consists of a solid enzyme immunoassay, based on specific substrates that allow 
the measurement of BCR-ABL endogenous activity. 
LeukoPredict works similarly to the phosphopeptide-based assay (Figure 18). The peptide is 
synthetic and interacts with a specific form with the enzyme domain ABL1 and the domain 
SH3 of the BCR-ABL enzyme164-166. 
The peptide is synthesized using solid phase Fmoc chemistry. A lysine has been 
functionalized with a biotin molecule to allow the peptide to be easily bonded to a solid 
substrate.  
The domain named “reporter” (Figure 19), with the EAIYAAPFAKKK sequence, is an 
optimized substrate for ABL1167. The domain named "targeting" (Figure 19), with the 
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Figure 19. ABL peptide scheme. Complete sequence and domains. 
APTYSPPPPP sequence, is a sequence rich of proline that is recognized by the SH3 
domain that mediates the interaction between peptides and proteins, greatly improving its 
specificity for the target. 
 
  
 
 
 
 
The LeukoPredict’s protocol foresees the following steps: 
1. Peripheral blood collection of the patient before and after treatment. 
2. Isolation of BCR-ABL enzyme presents in the patient’s blood using a specific lysis 
buffer. This lysis buffer is a creation of the university of Verona and is under patent 
application. 
3. Incubation of cell lysate in the ELISA plate coated with the peptide substrate. 
4. Washing the cell lysate. 
5. Detection of phosphorylation with biotin-labeled monoclonal antibody. 
6. Washes. 
7. Amplification of the signal by secondary and chromogenic antibodies. 
The ABL peptide is immobilized at the bottom of the wells of ELISA plate. In the presence of 
high enzymatic activity (translated in poor action of the TKI), the BCR-ABL enzyme adds 
phosphate groups to the ABL. If instead the TKI inhibits the action of the BCR-ABL enzyme, 
the amount of such phospate groups will decrease. This difference in enzyme activity is 
quantifiable across the fluorescence difference of the monoclonal antibody.  
The preliminary tests show the feasibility of this approach.  
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The K562 CML cell line was treated in the times indicated with 5 µM Imatinib (STI) and 16 
nM Dasatinib (Das) (Figure 20). The cells were lysed and 4 µg of the cell lysate was in 
contact with the immobilized ABL peptide. The data comes from three independent 
experiments. 
 
LeukoPredict test was developed by the University of Verona, and the product optimization 
tests will be carried out by their researches. The company DITTA DINO PALADIN has 
conducted the activities related to the industrialization process of the product.  
 
 
 
  
Figure 20. Time course analysis of BCR-ABL activity in K562 treated 
with the TKIs Imatinib (STI) and Dasatinib (Das). 
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2.3. INDUSTRIALIZATION PROCESS 
The assessment of an assay’s potential as a commercial IVD includes many different steps, 
preveeincluding as preliminary steps of Freedom to Operate and a pharmaco-economic 
analysis. These steps may be repeated and updated as increasing degrees of evidence are 
collected. 
Freedom to operate Analysis 
This kind of analysis is aimed at defining the level of risk related to products launched on the 
market. It’s important to look at the risk to interfere with third-party existing patents.  
Pharmaco-economic analysis 
With the current international situation, the disproportionate increase in costs of many new 
health technologies and the growing pressure to reduce the budget set aside for healthcare 
in most countries, it is becoming increasingly necessary to make and economic evaluation of 
health interventions.  
Pharmaco-economy is a relatively recent world that refers to the application of economy to 
pharmaco-therapy. The concepto comes from developed countries and specifically from 
Australia, where was adopted in the 80s by the pharmaceutical giants.  
The majority of these pharmaco-economic studies focus on three targets:168 
a. Economic evaluations to define the convenience of a new product both in the early 
and developing stages. 
b. Economic evaluations to justify the price of the product, identifying the key elements 
for fixing the prices in terms of production costs and market characteristics. 
c. Economic analysis to calculate the product payback. 
The pharmaco-economic departments of pharmaceutical companies are often under the 
supervision of the marketing department, 169 that is unlike the departments responsible for 
clinical studies that are autonomous. 
There are many different economic analyses.  
The cost-benefit analysis (CBA) is the most common and well known. It is an analysis of 
the expected balance of benefits and costs, including an account of previous alternatives 
and the status quo. In CBA, benefits and costs are expressed in monetary terms, and are 
adjusted for the time value of money. 
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Cost-effectiveness analysis (CEA) is a form of economic analysis that compares the 
relative costs and outcomes (effects) of different plans of action. Typically the CEA is used in 
the field of health services expressed in terms of a ratio where the denominator is a health 
gain from a measure (years of life, premature births averted, sight-years gained) and the 
numerator is the cost associated with the health gain. 
The more complex is the cost–utility analysis (CUA). This is a form of financial analysis 
used to guide procurement decisions. The most common and well-known application of this 
analysis is in pharmacoeconomics, especially health technology assessment (HTA). In 
health economics the purpose of CUA is to estimate the ratio between the cost of a health-
related intervention and the benefit it produces in terms of the number of years lived in full 
health by the beneficiaries. In the reference case analysis, the measure of utility must be a 
quality-adjusted life-year compatible health-related quality-of-life-score. 
In the health field, cost-effectiveness and cost-utility are often used interchangeable. 
In developed countries where it is possible to settle and control costs of health devices’ 
production and where health insurance is basically absolute, pharmaco-economics can 
clearly lead to improve the clinical decision-making process, mainly between different 
medical treatments that looks to be fairly similar. The principal aim shouldn’t be cost control 
but the improvement of efficiency to gain equity of access to health care.170In most 
developed countries the different healthcare systems defines who pays for medicine and 
how much. When there is a co-payment system there is a specific level of participation 
between parties: in developed countries the government covers more than the 60% of the 
cost.  
In developing countries, where it is a large percentage of the population doesn’t have free 
access to drugs and many people die from diseases for which there are preventive 
medicines, pharmacoeconomics should have a different approach and distinct 
characteristics. In addition to cost management, it’s important to make the use of resources 
more efficient and to gain new sources of funding so as to ensure the medical coverage to 
everybody. Therefore, the priority has been given to the macroeconomic analysis compared 
to single medicaments. In many developing countries the consumer pays directly the 70% of 
treatment’s cost. Furthermore, the Government is largely absent in defining mechanisms of 
treatment’s funding to make it accessible to all citizens. In several parts of Africa, Asia and 
Latin America the issue isn’t about choosing the most appropriate treatment but it’s about 
having access to the only available resource. Quality of life is off the table, it’s just about 
having the chance to survive to an infection treated with first generation antibiotics.  
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It is clear that if individual and social benefits of many medicines resulted in monetary terms 
and prices of medicine, this would lead to an uncontrollable increase in treatment prices. In 
this sense it the need to establish methodological compulsory and standard guidelines to 
encourage the governmental control and an objective comparison between different studies 
has been suggested. 171  
There are many different key elements to be taken into account when defining studyies’s 
criteria: 172 
a. The typology of economic analysis that has to be considered. 
b. Methods to be used in economic evaluation, procedures to develop them and needed 
criteria, social impact or economic outcomes resulting from specific therapeutic 
strategy. 
c. Ethical criteria that should lead the economic evaluation of medicaments. 
 
There has to be a total independence between the scientist and the investor. 
In this field of study exists a specific terminology, which is important to understand before to 
facing this kind of analysis. In succession these are the most important terms:173 
 
Quality-Adjusted Life-Year (QALY): a year of life lived in perfect health. 
Quality-Adjusted Life Expectancy (QALE): the average number of QALYs adjusted of life 
expectancy. 
Competing alternative: An alternative practice for diagnosing or treating the disease you 
are studying in a cost-effective analysis.  
Average Cost-Effectiveness Ratio: the net cost of an intervention divided by its net benefit 
gain versus the no-intervention option.  
Incremental Cost-Effectiveness Ratio (ICER): Between two competing alternatives, it is 
the ratio of the change in costs and the incremental gain in benefit.  (𝐶𝑜𝑠𝑡 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 2 − 𝐶𝑜𝑠𝑡 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 1)(𝑄𝐴𝐿𝐸 2 − 𝑄𝐴𝐿𝐸 1)  
The intervention less effective is usually positioned on the right-hand side of the equation, 
ensuring that the ratio will be positive if the intervention costs money but improves health 
and negative if the intervention saves money and improves health.  
Health-related quality-of-life (HRLQ) score: a numerical evaluation of life in a given health 
state anchored between 0 (death) and 1 (perfect health). These scores are used to adjust 
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life-years to quality-adjusted life-years (QALYs). Thus, a year of life lived at an HRLQ of 0.7 
is equivalent to 0.7 QALYs (or 0.7 years of perfect health). 
Discounting Future Costs: medical interventions, especially preventive interventions, often 
result in decreased future medical costs that must be accounted for in present-day terms. 
Humans have a tendency to place a lower value on future events than on events that occur 
in the present. This phenomenon is called discounting. In cost-effectiveness analysis, all 
future cost and effectiveness values must be discounted into their net present value. 174 The 
Panel on Cost-Effectiveness in Health and Medicine bases the recommended discount rate 
on a valuation that is roughly equal to the real rate of return on government bonds. Because 
this rate varies over time and the reference case is concerned with making all cost-
effectiveness analyses comparable, the panel has settled on a rate of 3 percent. However. 
Standards vary from country to country. 
In Europe this value is established by NICE guidelines, which estimates a discount of 3,5%. 
The general formula for discounting future costs is: 
 
Discounted cost = !"#$ !" !!! !"#"$% !"!#$(!!!"#$%&'( !"#$)!"#$% !" !!! !"#"$% 
 
Decision analysis model: a model used to calculate the expected value of a given health 
strategy. Decision analysis models are the most frequently used means for calculating 
incremental cost-effectiveness ratios.  
Markov model: a decision analysis model that incorporates an element of time. 
Sensitivity analysis: an analysis that varies model inputs over their plausible range of real-
world value in order to examine how they might influence model outputs. 
Tornado diagram: a test of the effect of error on model outputs in which each variable of 
interest within the model is sequentially varied over a range of plausible values holding all 
other variables constant. Graphs of the variables are stacked according to their overall 
influence on the model, so the output assumes the appearance of a tornado.  
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3. AIMS 
The lack of prognostic factors that could unbalance physicians towards a certain tyrosine 
kinase inhibitor compared with another one makes the therapeutic drug monitoring really 
essential to evaluate the therapeutic efficacy and potential cross-resistances.  
This project has been focused on CML therapy, facing the subject from two totally different 
angles: the therapeutic drug monitoring and the prediction of response to treatment.  
3.1. MONITORING THERAPY 
As stated above, the therapeutic monitoring gold standard technoque is qRT-PCR Real Time 
through quantification of molecular response because of its ability of quantifying and 
identifying until few copies of BCR-ABL transcripts. Then, we developed two new kits based 
on qRT-PCR Real Time to identify and measure the translocation t(9;22)(q34;11) and its 
variations, p210BCR-ABL (RQ-BCR-ABL p210 One-Step) and p190BCR-ABL (RQ-BCR-ABL p190 
One-Step), to have a full picture of disease’s monitoring.  
3.2. PREDICTION OF THERAPEUTIC RESPONSE 
Currently there’s no way to predict the therapy’s effect with tyrosine kinase inhibitor on a 
each patient. For this purpose LeukoPredict has been developed LeukoPredict, an in vitro 
test to screen simultaneously the inhibitory potential of several BCR-ABL-targeting drugs, 
and to obtain the percentage of inhibition compared to the same non-treated samples. 
LeukoPredict test was developed by the University of Verona, and we have conducted some 
activities related to the industrialization process of the product.  
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4. METHODS 
4.1. DEVELOPMENT AND VALIDATION OF THE NEW “RQ-BCR-ABL P190 ONE-STEP” 
The choice of primers and probes was done following the European LeukemiaNet (ELN) 
recommendations85 
We carried out validation experiments on the “Applied Biosystems 7500 Fast-Dx Real-Time 
PCR System (Applied Biosystems)” instrument (abbreviated as ABI 7500 Fast Dx). 
As controls we used the standard 5-point curve of the “REALQUALITY RQ-BCR-ABL p190 
STANDARD” kit (100-1,000,000 copies for 5 µL) for BCR-ABL p190 and for ABL, calibrated 
checking the ABL target using the ERM -AD623 (IRMM), certified reference material. 
To determine the specificity and diagnostic sensitivity values on ABI 7500 Fast Dx, a total of 
17 RNA (leukocyte pellets and cell lines) were analysed: 
- 4 RNAs derived from serial dilutions of IVS-0032 Clonal Control RNA; 
- 1 RNA derived from negative cell line for BCR-ABL p190 translocation; 
- 6 RNAs of patients with ALL; 
- 1 RNA of patient with CML (positive for BCR-ABL p210); 
- 3 IVS-0032 Clonal Control RNA; 
- 2 Control RNA: High and Low BCR-ABL1 p190 Control (ipsogen BCR-ABL1 mbcr 
Controls Kit) 
The negativity / positivity of investigated translocation samples was verified by the supplier 
using another CE IVD method (ipsogen® BCR-ABL1 mbcr). IVS-0032 Clonal Control RNAs 
are commercial controls positive for the p190BCR-ABL translocation. 
The rarity of investigated translocation has complicated the finding of more samples and the 
finding of collaborations in order to subject the product to external validation.  
All the samples analysed during this validation were processed according to the buffy coat 
method175 (with red blood cell lysis buffer) and then the RNA was extracted from leukocyte 
pellet using the following kits: 
Automatic: Maxwell® 16 System (Promega) 
Manual: RNeasy Mini Kit (QIAGEN) 
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Evaluation Criteria for Sample Analysis 
Working in replicates, it is sufficient that there is amplification in one of the wells of the BCR-
ABL p190 target to give a positive result; instead, to give a negative result, it is necessary 
that there is not any amplification in any of the wells. 
In the case of the positivity of at least one of the replicates in the quantitative analysis, the 
use of the standard curve for BCR-ABL p190 and ABL allows to transform the Ct values of 
the investigated samples into ABL copy numbers (ABL)CN and BCR-ABL p190 (BCR-ABL 
p190)CN.  
The eligibility criterion required for sample analysis in which MMR is evaluated is that the 
number of ABL copies is ≥ 10000. 85 This requirement allows obtaining the optimum 
sensitivity level for the specific survey type. 
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4.2. DEVELOPMENT AND VALIDATION OF THE NEW “RQ-BCR-ABL P210 ONE-STEP” 
The choice of primers and probes was done following the European LeukemiaNet (ELN) 
recommendations85 
We conducted validation experiments on the “Applied Biosystems 7500 Fast-Dx Real-Time 
PCR System (Applied Biosystems)” tool (abbreviated as ABI 7500 Fast Dx). 
As controls we used the standard 5-point curve of the “REALQUALITY RQ-BCR-ABL p210 
STANDARD” kit (100-1,000,000 copies for 5 µL) for BCR-ABL p210, ABL and GUSB 
calibrated checking the ABL target using the ERM-AD623 (IRMM), a certified reference 
material of known titer, and 1st World Health Organization (WHO) International Genetic 
Reference Panel for quantitation of BCR-ABL. 
To determine the specificity and diagnostic sensitivity values on ABI 7500 Fast Dx, a total of 
78 RNA (leukocyte pellets and cell lines) were analysed: 
- 50 RNAs of patients with CML; 
- 10 RNAs of patients with AML (acute myeloid leukemia); 
- 8 RNAs of patients with ALL (acute linfoblastic leukemia) and positives for p190 
variant; 
- 4 RNAs WHO Sensitivity Panel; 
- 6 RNAs IVS-0011 Sensitivity Panel. 
 
The negativity / positivity of the samples detected by the validated device was established by 
double-sample analysis with RQ-BCR-ABL p210 One-Step product. In case of disagreement 
between the methodology under examination and the reference test (ipsogen® BCR-ABL1 
Mbcr IS-MMR kit), other CE IVD assays RS-BCR-ABL p210 kit (AB ANALITICA) and/or the 
RS-BCR-ABL p190 kit (AB ANALITICA) were used. 
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4.3. LABNET VALIDATION OF “RQ-BCR-ABL P210 ONE-STEP” 
RQ-BCR-ABL p210 One-Step has undergone further clinical validation through Labnet 
network. Specifically, this validation has been conducted in three different national referece 
laboratories (Bologna, Torino, Napoli). In each center the same samples have been tested 
with our device and with the routine method in use. 
Clinical samples 
30 RNA samples, representative of the four levels of the disease (10%, 1%, 0.1%, 0.01%), 
were distributed to the three laboratories by the Haematologic center of Torino. They have 
been prepared with the Maxwell extractor (Promega), using the Maxwell® 16 LEV 
simplyRNA Blood kit. 
Dilutions at 40ng/µL of the samples were prepared and a final amount of 200ng/5µL was 
tested together with a secondary reference material (RNA Reference of ELITech Group and 
RNA REFERENCE of AB ANALITICA). 
 
A total of 6 runs per each center (3 plates with our kit, 3 plates with routine assay) have been 
performed. In all three centers the instrument used was the Applied Biosystems 7900HT 
Fast Real-Time PCR. 
 
Methods used in each laboratory routine: 
Napoli: 'in-house' reagent for retrotrascription/amplification with Ipsogen standard (BCR-
ABL1 Mbcr IS-MMR).   
Bologna: BCR-ABL1 Mbcr b3a2 & b2a2 kit (Ipsogen), which uses the two-step method. The 
standard controls are contained in the kit and are unique plasmids.  
Torino: Kit BCR-ABL P210 ELITe MGB (ELITechGroup), kit that, like our device, is a One-
Step method. The standard controls are those contained in the kit and are unique plasmids. 
 
Calculation of Conversion Factors (CF): 
In the last few years, the need arose to standardize molecular monitoring of the deep 
Molecular Response (deep MR) and to define guidelines for interpreting results. 2 Definition 
of the International Scale for BCR-ABL p210 detection and quantification has been helped 
by the recent development of the first reference panel accredited by the World Health 
Organization (1st World Health Organization (WHO) International Genetic Reference Panel 
for quantitation of BCR-ABL translocation by RQ-PCR176). 
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Therefore reference kits have been developed and marketed to calculate CF in each 
laboratory. These reference kits are composed of total RNA blends of a cell line containing 
BCR-ABL translocation (9.22) p210 b3a2 in a normal cell line RNA. Such mixtures 
correspond to a Reference Title that results from a calibration performed using the 1st World 
Health Organization (WHO) International Genetic Reference Panel for quantitation of BCR-
ABL translocation by RQ-PCR (NIBSC, UK, cod 09/138). This value corresponds, for each 
RNA mixture, to the transient mRNA t (9.22) p210 percentage compared to the ABL mRNA.  
The conversion factors of the three centers were calculated in Napoli by analysing the data 
obtained with the PHILADELPHIA P210 RNA Reference Kit (ELITech Group) and using the 
Bland-Altman statistical method. 
The CFs calculated for “RQ-BCR-ABL p210 One-Step” device in each center were: 
Orbassano (Torino) = 0.8876 
Napoli = 0.9932 
Bologna = 0.8625 
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4.4. PREDICTION OF THERAPEUTIC RESPONSE: LEUKOPREDICT 
INDUSTRIALIZATION ACTIVITIES. 
4.4.1. FREEDOM TO OPERATE ANALYSIS (FTO) 
A freedom to operate (FTO) analysis is aimed at defining the level of risk related to the 
expected entry into market of a product or of a service, to the extent they might interfere with 
third parties’ patent rights (or other intellectual property rights, as the case may be).  
For this analysis, Esp@cenet and Fampat database (from Questel Orbit) have been used. It 
must be pointed out that the patent applications are published 18 months after filing. Before 
their publication, such documents cannot be accessed or consulted and so they do not 
appear in any database. Therefore, possible patent applications filed during the last 18 
months are not considered in this analysis. It is generally advisable that a supplementary 
FTO analysis is conducted once the product is ready to go on the market, to make sure the 
18-month window is uncovered and all risks are taken into account. The relevant patent 
landscape for the FTO has been identified within applicable International Patent 
Classification (IPC) classes, using keywords (that have been masked and truncated to have 
maximum coverage in the search). 
For the assessment of risk profiles of interference between the technology and third party 
rights, the following conditions were applied: - The freedom to operate is assessed only with reference to third party patents which 
(i) are pertinent with respect to the technology, (ii) have been actually granted at the 
date of the present analysis, or (iii), in case of patent applications, there is a chance 
such applications reach grant shortly, thus becoming a threat to practice the 
technology. - The literal infringement occurs when the invention being considered in infringement 
repeats all the (characterizing and characterized) elements of the claim, so that even 
the absence of one only of said elements leads to a conclusion of non-infringement. - Since the FTO analysis implies a comparison between the technology and currently 
valid and enforceable claims, it is assumed that the technology, will not change 
significantly and, to the purposes of the FTO, the present knowledge faithfully 
describes the main feature of such the technology. - Because of the territorial nature of patents, the FTO risks must be always determined 
according to the actual validity and enforceability of third parties’ patents in specific 
countries and markets, not in general. 
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For the purposes of the FTO analysis, the Technology can be segmented in different 
aspects: 
4.4.1.1. Samples preparations 
As described first, LeukoPredict is based on the measurement of BCR-ABL activity. In order 
to measure the activity of this kinase, it is crucial to maintain its stability during the 
preparation of the samples. Indeed, the enzyme seems to be very susceptible to degradation 
by lytic enzymes derived from degranulation activity of polymorphonucleated cells (PMN). 
In order to preserve the best morphology of cells and non-lytic activity from PMN, a particular 
protocol has been developed. In particular, peripheral or bone marrow whole blood can be 
treated with TKIs for 2h at 37 °C. After TKIs treatments, blood samples are subjected to red 
blood cells (RBCs) lysis with RBCs lysis buffer.  
Subsequently, white blood cells are counted and left on ice. 
After treatments and RBC lysis, cells are lysed in the appropriate prechilled buffer: isotonic 
lysis + protease inhibitors. 
The composition of this lysis buffer has been protected by a patent application. 
Then, the supernatant is collected by centrifugation for 10-15 minutes at the maximum 
speed in a microfuge (13.000 rpm, 4°C). After the centrifugation step, it is possible to 
proceed with protein quantification by Bradford analysis using Bio-Rad protein assay reagent 
(Bio-Rad Laboratories, Hercules, CA, USA). 
It must be pointed out that the protocol described above is not yet definitive and some 
modifications might still occur. This aspect was considered during the research. 
The following landscaping strategy has been used to identify relevant patent documents and 
valid claims: - Keywords in the title, abstract or independent claims: 
Lysate preparation, lysis buffers and/or solutions, lysis method,  protein activity 
analysis, protease inhibitors, isolation, extraction, composition, EDTA, pepsatin, 
DDT/dithithreitol, benzamidine, PAO/Phenylarsine oxide, triton X, Tris-HCL, NaF, 
Sodium orthovanadate, supernatant, centrifugation, blood, protein, biological sample. - International Patent Classification: 
o C12N 1/00: Micro-organisms, e.g. protozoa; Compositions thereof (medicinal 
preparations containing material from protozoa, bacteria or viruses A61K 35/66, 
from algae A61K 36/02, from fungi A61K 36/06; preparing medicinal bacterial 
antigen or antibody compositions, e.g. bacterial vaccines, A61K 39/00); 
Processes of propagating, maintaining or preserving micro-organisms or 
compositions thereof; Processes of preparing or isolating a composition 
containing a micro-organism; Culture media therefor [2006.01]. 
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o C12N 9/00: Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof 
(preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; 
medicinal preparations containing enzymes or proenzymes A61K 38/43; enzyme 
containing detergent compositions C11D); Processes for preparing, activating, 
inhibiting, separating, or purifying enzymes. 
o G01N 1/00: Sampling; Preparing specimens for investigation. 
o C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; 
Cultivation or maintenance thereof; Culture media therefor. 
o C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic 
engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; 
Use of hosts therefor (mutants or genetically engineered micro-organisms C12N 
1/00, C12N 5/00, C12N 7/00; new plants A01H; plant reproduction by tissue 
culture techniques A01H 4/00; new animals A01K 67/00; use of medicinal 
preparations containing genetic material which is inserted into cells of the living 
body to treat genetic diseases, gene therapy A61K 48/00; peptides in general 
C07K). 
o G01N 33/00: Investigating or analyzing materials by specific methods not 
covered by groups G01N 1/00-G01N 31/00. 
o G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing 
involving biospecific ligand binding methods; Immunological testing (measuring or 
testing processes other than immunological involving enzymes or micro-
organisms, compositions or test papers therefor; processes of forming such 
compositions, condition responsive control in microbiological or enzymological 
processes C12Q). 
o C12Q 1/00: Measuring or testing processes involving enzymes or 
microorganisms (measuring or testing apparatus with condition measuring or 
sensing means, e.g. colony counters, C12M 1/34); Compositions thereof; 
Processes of preparing such compositions. 
 
4.4.1.2. Samples analysis 
The BCR-ABL activity is measured through a kinase assay. The peptide substrate (ABL-
biosensor peptide, CEAIYAAPFAKKK165 is immobilized on a neutravidin-coated surface. The 
phosphorylation that occurs after the interaction between the kinase present in the samples 
and the immobilized peptide can be detected with phospho-specific primary antibody and an 
enzyme-conjugated secondary antibody. Subsequently, upon addition of a suitable substrate 
for the conjugated enzyme, the chromogenic, luminescent, or fluorescent readout is 
quantified. However, other methods can be used for detecting the phosphorylation. These 
  47 
methods can include the use of fluorescently labelled antibodies, as well as the use of 
biotinylated reagents and their recognition with fluorescently labelled streptavidin. 
The following strategy has been used: - Keywords in the title, abstract or independent claims: 
Kinase assay (and tyrosine kinase assay), chronic myeloid leukemia (CML), 
diagnosis tests, BCR-ABL, diagnosis kit, molecular diagnosis, screening, profiling, 
drug selection, monitoring response to treatment, measuring enzyme activity, blood, 
enzyme, enzyme assay, enzymatic activity, phosphorylation, peptide arrays, 
immunoassay, immobilized peptide, immobilized substrate, tyrosine kinase inhibitor 
(TKI), ABL peptide biosensor, biosensor peptide, biomarker, Imatinib, Dasatinib, 
ponatinib.  - International Patent Classification: 
o G01N 33/00: Investigating or analyzing materials by specific methods not 
covered by groups G01N 1/00-G01N 31/00. 
o G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; 
Testing involving biospecific ligand binding methods; Immunological testing 
(measuring or testing processes other than immunological involving enzymes 
or micro-organisms, compositions or test papers therefor; processes of 
forming such compositions, condition responsive control in microbiological or 
enzymological processes C12Q). 
o G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor. 
o C12Q 1/00: Measuring or testing processes involving enzymes or micro-
organisms (measuring or testing apparatus with condition measuring or 
sensing means, e.g. colony counters, C12M 1/34); Compositions therefor; 
Processes of preparing such compositions. 
In particular C12Q 1/48: involving transferase. 
o C40B 30/00: Methods of screening libraries (C40B 30/08: by measuring 
catalytic activity). 
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4.4.2.  COST-EFFECTIVENESS ANALYSIS: HEALTH ECONOMIC (DECISION-
ANALYTIC) MODEL FOR THE EARLY LEUKOPREDICT TEST IN CML 
Decision-analytic modeling was used for the analysis. To ensure optimal methodological 
approach it was used a methodological checklist of modeling companion diagnostics in 
economic evaluations of targeted oncology therapies by Double et al. 177.  
The key elements of model structure and rationale for the analysis are present in the 
following table: 
Component Summary 
Time horizon 
Eight years in the model base case equal to a median follow-
up of eight years in the study Neelakantan et al.178 
Outcomes LYG and QALYs 
Methods used to generate 
results 
Markov model; cohort expected value analysis 
Cycle length Three months 
Transition probabilities Transition probabilities presented in Table 5 
Discount rate 3.5% of costs and outcomes 
Table 4. Summary of model structure and rationale. Legend: LYG – life years gained, QALY – quality adjusted 
life years  
A state transition Markov model with a cycle length of three month’s cycle length was used in 
combination with decision tree was used to evaluate the cost-effectiveness of management 
strategy with use of LeukoPredict. 179-182  
4.4.2.1. Strategies compared 
Decision analytic model compared two strategies: 
1) CML standard of care strategy - In the base-case analysis patients receive first-line treatment in line with real-world 
settings, 33,33% per TKI (include Imatinib, Dasatinib and Nilotinib) - In the scenario analysis 1 patients receive first-line treatment with Imatinib. - In the scenario analysis 2 patients receive first-line treatment with Imatinib but costs 
decreases of Imatinib due to the generic entry was modeled, with prioritizing patients 
to receive Imatinib in the first line treatment due to the lower costs. 
2) LeukoPredict test as a companion diagnostic test added to the standard of care 
strategy. 
It is possible to triage patients based on their drug resistance potential and thus allowing 
selection of a drug which will have a best possible initial response measured by early 
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molecular response (EMR). The assumption used in the published CML economic 
evaluations that patients were taking only hydroxycarbamide after CML disease progression 
to accelerated phase and blast crisis was reused for the purpose of this analysis.  183-189  
In this analysis, in the both treatment arms, patients received stem cell transplant (SCT) or 
hydroxycarbamide, as a third-line treatment after TKI failure. 
 
4.4.2.2. Model structure 
A Markov model was developed to reflect the natural history of CML patients as suggested 
in the current guidelines recommendations182 and based on previously published decision-
analytic models for management of CML. 182-189 During each 3-month cycle, patients have 
the following possibilities: continuing on the first; switching to the second line therapy due to 
the non-responding measured by EMR after 6 months; switching to the third line due to the 
non-responding to the second-line therapy after 12 months; progression of disease to the 
accelerated phase and blast crisis; and death (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.State-transition (Markov) model influence diagram of CML natural history of disease. 
Legend: AP – accelerated phase; BC – blast phase 
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The clinical management algorithm is presented in Figure 22 and Figure 23. Patients will 
have a treatment switch after first-line treatment failure to Imatinib or 2nd generation TKIs 
Dasatinib and Nilotinib in the base-case analysis. In the scenario analysis, after receiving 
100% Imatinib as first-line treatment patients can have a treatment switch to Dasatinib and 
Nilotinib in equal proportions.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 22.Treatment arm as scenario 1 and 2.  
Legend: ST – standard treatment; SCT – stem cell transplantation; M – Marcov model 
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Figure 23. Standard treatment (ST) arm real-world practice.  
Legend: SCT – stem cell transplantation; M – Marcov model 
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In modeling a diagnostic test, practical application of Bayes’ theorem allows to incorporate 
the test’s sensivity and specificity for the analysis. Prevalence of presence/absence of 
resistance to TKIs and diagnostic test sensitivity and specificity have been used to calculate 
various events probabilities employed Bayesian revision. 190 The proportions of patients 
testing positive or negative was based on the assumed accuracy of the LeukoPredict test in 
the following way: 
 
True positive (TP) = Prevalence of resistance * sensitivity 
False positive (FP) = (1 – Prevalence of resistance) * (1 – specificity) 
False negative (FN) = Prevalence of resistance * (1 – sensitivity) 
True negative (TN) = (1 - Prevalence of resistance) * specificity 
Sensitivity = TP/(TP+FN) 
Specificity = TN/(TN+FP) 
 
Based on the proportion of those four groups patients will have three possible treatment 
paths as depicted in Figure 24. True negative and false negative patients will have the same 
treatment sequence as a standard of care arm and will not give any incremental value to the 
LeukoPredict test. True positive and false positive will have received treatment, which will be 
without treatment failure due to the primary resistance and those patients will represent a 
group of patients with biggest beneficial of using LeukoPredict. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 24. LeukoPredict arm decision tree as a companion diagnostic test added to the 
standard treatment 
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4.4.2.3. Decision analytic modelling methods and assumptions 
The following methods and assumptions were used in the modeling: 
• Sensitivity and specificity of the diagnostic tests cannot be considered separately 
due to the facts that they are negatively correlated191. Therefore, inputs parameters 
regarding diagnostic accuracy for the economic evaluation of the diagnostic test 
ideally should be linked to the positivity threshold. This allows identification of the 
“Optimal Operating Point,” or test threshold with the sensitivity and specificity pair at 
which the test is most cost-effective.192,193In the future, identified optimal threshold 
should be used for the base-case analysis in economic evaluation and the 
optimization of future clinical trials.194 
• The LeukoPredict test is modeled as a point-of-care diagnostic test, where human 
intervention is minimized. It assumed for the purpose of the analysis that one hour of 
a laboratory technician labor is needed when the test is done "on-the-fly" on blood 
samples in the first hours of the treatment. The costs for cell cultures and in vitro 
drug testing will be much higher, and they are not part of this analysis.  
• Patients will be checked for treatment efficacy using EMR with two tests, at three 
and six months, and additional tests in between as recommended by guidelines.  
• Patients who achieved a negative EMR (and the indicator of an unimproved health 
status) will switch from the initially selected TKI to an alternative TKI and evaluated 
for outcomes through the additional time in the model.  
• Conversely, patients who achieved a positive EMR (an indicator of an improved 
health status) were assumed to continue on the initially selected TKI and evaluated 
for outcomes over the same time frame.  
• After switching to the second line therapy, the patient can experience treatment 
failure again which will lead to third line treatment which was assumed to be 
allogenic transplantation.  
• The models assume perfect patient adherence to TKI-based treatment across all 
treatment modalities.  
• Mortality is based on statistics of overall survival (OS) stratified by treatment group.  
• In additional scenario analysis, the price of Imatinib was assumed to follow the pre-
specified decrease starting in 2016.  
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4.4.2.4. Data inputs 
Transition probabilities 
The foundation for analysis was the data from a study conducted in the UK.178Transition 
probabilities regarding treatment response defined by EMR as depicted in Table 5, as well as 
survival in relation to the EMR status at three and six months were derived from the source 
mentioned above. Some of the transition probabilities, as a progression to accelerated phase and 
blast phase were utilized from the economic model by Padula et al. 186, after checking primary 
source of data and adaptation for three months’ cycle. Taking into account that study used in 
Padula et al. 186 were confirmed by a panel of CML experts, all membe rs of the European 
LeukemiaNet (ELN) CML committee, as well as that study, was non-industry sponsored this source 
can be considerate as a highly relevant. Also, this is the only published model that uses EMR as a 
surrogate endpoint for the survival, and treatment switch. 
Probabilities Proportion (95% CI) Sources 
Imatinib 
3 months EMR non-responders 0.24 (0.15-0.34) 
178 3 months EMR re-responders 0,23 (0,18-0.28) 
6 months EMR non-responders 0.16 (0.08-0.27) 
Switch to Dasatinib 0.5 (fixed) 186 
Switch to Nilotinib 0.5 (fixed) 186 
Progress to AP/BP 0,004 (0.003-0.006) 195,196 
Dasatinib 
3 months EMR non-responders 0.16 (0.11-0.21) 196 
6 months EMR non-responders 0.11 (0.07-0.16) 196 
Switch to Imatinib 0.15 (fixed) 186 
Switch to Nilotinib 0.85 (fixed) 186 
Progress to AP/BP 0.004 (0.003-0.005) 196 
Nilotinib 
3 months EMR non-responders 0.09 (0.06-0.14) 195 
6 months EMR non-responders 0.03 (0.01-0.06) 195 
Switch to Imatinib 0.15 (fixed) 186 
Switch to Dasatinib 0.85 (fixed) 186 
Progress to AP/BP 0.001 (0.0006-0.003) 195 
Common probabilities for all TKI 
Fraction of treatment failure due to the 
intolerance 
0.23 (0.16-0.29) Figure 24 
Transition from AP to BP 0.27 (0.21-0.32) 187 
Table 5. Base case transition probabilities for the standard treatment arm.  
Legend: EMR – early molecular response, AP – accelerated phase, BP – blast phase. 
A meta-analysis for treatment failure in the LeukoPredict arm (including non-responder and 
intolerant) from the cost-effectiveness analysis186 was re-done to disaggregate transition 
probabilities to non-responders and intolerant.  
To adequately triage patient switching to the third line treatment with a possibility to receive stem 
cell transplant (SCT) or hydroxycarbamide, age-related proportions of patients eligible for receiving 
a stem cell transplant was determined from the literature (Table 6)	187. 
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Age (years) at which TKIs 
fail Patients receiving SCT 
50–59 60% 
60–64 40% 
65–69 15% 
70–74 5% 
75+ 0% 
																	        Table 6. Age-related proportions of patients receiving a stem cell transplant 
 
 
4.4.2.5. Survival 
Survival for the purpose of this analysis was based on an overall (OS) and progression-free 
survival (PFS), additionally adjusted for the differences of being in specific health state (chronic 
phase or advanced phases of the CML).  
Overall survival (OS) was informed by study Neelakantan et al. 	178	conducted in the UK. This study 
reports the 8-year probability of overall survival according to the BCR-ABL1 transcript level at three 
and six months as presented in Figure 25. The study confirms that initial EMR is a prognostic 
factor for overall survival already with the first measurement at three months and at six months as 
well. Also, this study allows modeling survival based on dynamic changes of the EMR at three and 
six months, dividing initial cohort into four groups as depicted in Figure 25. The prognostic value of 
the EMR assessment was confirmed being the independent prognostic factor and not affected by 
treatment switching. 
 
 
 
 
 
 
 
 
 
 
Figure 25. Overall survive according to the BCR-ABL transcript level at 
three and six months 
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Survival in the advanced phases of the CML was reported as the average life expectancy of 9.6 
months for accelerated phase and life expectancy of 3–6 months for blast crisis, according to 
National Institute for Health and Clinical Excellence’s guidance (NICE) final appraisal determination 
(FAD) for second-line, high-dose Imatinib, Dasatinib, and Nilotinib for CML. 185  
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4.4.2.6. Costs 
Two main categories of resource utilization and costs are be included in the analysis: LeukoPredict 
and drug acquisition costs and follow-up costs. The costing index year for the analysis was 2016, 
and all cost data were adjusted for inflation, using the Hospital and Community Health Services 
Index. 197  
LeukoPredict and drug acquisition costs 
The expected costs of LeukoPredict test and resource use associated with cost were estimated in 
the communication with the client, as presented in Table 7. 
Test/Resource use Unit cost (£) 
LeukoPredict (Point-of-care testing) 129 
One additional blood sample withdrawal 12 
1-hour labor of a laboratory technician 13 
Table 7. LeukoPredict cost and resource use 
The cost of drugs was divided into the three subcategories taking into account differences in dose 
and frequency of usage primarily between first- and second-line treatments. All costs for first-line 
(Table 8) and second-line (Table 9) treatments were informed by the NICE technology appraisal 
guidance. 
Drug 
Dose and 
frequency 
Cost per pack (£) 
3-month cost 
per patient (£) 
Imatinib (400 mg 30 tablet pack) 400 mg once daily 1836.48 5509.44 
Nilotinib (150 mg 112 tablet pack) 300 mg twice daily 2432.85 7785.12 
Dasatinib (100 mg 30 tablet pack) 100 mg once daily 2504.96 7514.88 
Table 8. First-line CML treatment drug cost 
	
Drug 
Dose and 
frequency 
Cost per pack 
(£) 
3-month cost 
per patient (£) 
Dasatinib (100 mg 30 tablet pack) 100 mg once daily 2504.96 7514.88 
Nilotinib (200 mg, 112-cap pack) 400 mg twice daily 2432.85 7785.12 
Imatinib (400 mg 30 tablet pack) 400 mg twice daily 1836.48 11018.88 
Table 9. Second-line CML treatment drug cost 
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The cost for the third-line treatments is presented in Table 10. Peninsula Assessment Technology 
group estimated ongoing drug and monitoring costs after SCT as a weighted mean cost per month 
of £113. 187  
Treatment 
Dose and 
frequency 
Cost per pack (£) Cost per patient (£) 
Hydroxycarbamide 20–30 mg/kg daily 
10.47 per 500 mg, 
100-capsule pack 
36 
(three-month cycle) 
Stem cell transplant (SCT) 
for third line treatment 
- - 83247 
Ongoing drug and 
monitoring cost after SCT 
- - 346 
Table 10.Third-line CML treatment. Legend: SCT – stem cell transplantation 
Imatinib price adjustment after generic entry in 2016 was introduced into scenario analysis. Study 
by Conti et al.  198 reported on the drug–specific cost trajectories after generic entry, as well as per 
patient, per month cost trajectory of Imatinib-based therapy utilized as follows: (i) 100% of the 
branded treatment cost prior to generic entry for the first six months, (ii) 60% to 80% for the second 
six months following generic entry and (iii) 10% to 30% thereafter. 
4.4.2.7. Follow up costs 
A range of medical management costs, including nurse treatment, consultant outpatient visits, 
bone marrow tests, and hospitalization (without drugs) was also included in the analysis. The cost 
of a routine appointment and their frequency, as well as resource use per drug and health state, 
are sourced from the Novartis industrial submission as presented in Table 11 and Table 12.   
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Month No. of routine appointments 
Cost of routine appointments (£) 
(first and second line therapy) 
1 3 422 
2 1 141 
3 0 0 
4 1 141 
5 0 0 
6 1 141 
>7 2 282* 
Table 11. Cost of routine appointments 
	
Phase Imatinib (£) Dasatinib (£) Nilotinib (£) 
CP (0, 422) (0, 422) (0, 422) 
AP 94 94 94 
BP 186 186 186 
Table 12. Resource use, excluding drugs 
 
4.4.2.8. Analysis 
The analysis was performed from a perspective of the UK NHS over the eight years’ time horizon. 
In line with NICE (National Institute for Health and Care Excellence) recommendations, all costs 
and outcomes beyond the first year were discounted at 3.5% annually.199 LeukoPredict was 
considered cost-effective if the incremental cost-effectiveness ratio (ICER, which is calculated by 
dividing difference in cost between two arms by difference in quality-adjusted life years) was below 
the lower-bound willingness-to-pay threshold of £30,000/QALY.199 
 
4.4.2.9. Threshold analysis 
The laboratory data regarding Bcr/Abl activity variation after TKI treatment of cell lines 
(responders-K562 and resistant-BaF T315I), depending on the resistance to TKIs and presence of 
the Bcr-Abl mutations were used for estimation of the sensitivity and specificity of the test (Figure 
26).   
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In addition, threshold analysis was undertaken to identify “Optimal Operating Point” as a test 
threshold with the most cost-effective sensitivity and specificity profile. ICER was calculated with 
varying positivity thresholds linked to the sensitivity and specificity of LeukoPredict test. 
 
4.4.2.10. Sensitivity analyses 
Uncertainty about data inputs was evaluated in deterministic one-way and two-way sensitivity 
analysis. In the one-way analysis, each model’s parameter was varied individually while holding 
other variables fixed at base-case values to evaluate the impact of each variable at ICER. 
 
 
 
  
Figure 26. Sensitivity and specificity of LeukoPredict test as a function of the threshold on 
BCR/ABL activity variation. 
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5. RESULTS 
5.1. DEVELOPMENT AND VALIDATION OF THE NEW “REALQUALITY RQ-BCR-ABL P190 
ONE-STEP” 
5.1.1. DIAGNOSTIC SPECIFICITY AND SENSITIVITY 
Because of p190BCR-ABL CML represents only 1% of patients with CML, a small number of samples 
was available for validation.  
All 5 negative samples analysed were considered suitable for analysis. The assay was able to 
properly identify 5 out of 5 negative samples for BCR-ABL p190 translocation obtaining results that 
agree with the expected. 
All of the 7 positive samples analysed were considered suitable for the analysis. The assay was 
able to correctly identify 7 out of 7 positive samples for the BCR-ABL p190 translocation. 
Specificity and diagnostic sensitivity were defined as follows: 
DIAGNOSTIC SPECIFICITY = Negative results / total negative samples: 
6/6 = 100% 
DIAGNOSTIC SENSITIVITY = Positive results / total positive samples: 
 11/11 = 100% 
 
5.1.2.  ACCURACY 
The accuracy was calculated as the percentage of correct results in relation to the total number of 
tests. The total accuracy of RQ-BCR-ABL p190 One-Step is 100% 
 
5.1.3. ANALYTICAL SPECIFICITY 
The analytical specificity of the kit is guaranteed by an accurate and specific selection of primers 
and probes and the use of stringent amplification conditions.  
Alignment of primers and probes in the most important databases showed no non-specific pairing.  
5.1.4. REPRODUCIBILITY 
In order to determine the assay variability (variability among replicates of the same sample in 
different analysis sessions), dilutions of extracted total RNA from positive human cell lines for 
BCR-ABL p190 translocation e1a2 were tested in five replicates in five consecutive analysis 
sessions.  
The variability coefficient (CV) of the device was determinate using the cycle threshold value (Ct) 
of each point, dividing the mean value of the standard deviation of Ct (Ct SD) for the mean Ct 
value calculated by the instrument (Ct mean). 
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 𝐂𝐕 = 𝐶𝑡 𝑆𝐷 𝑥 100𝐶𝑡 𝑚𝑒𝑎𝑛  
 
 
The variability coefficient on the ABI 7500 Fast Dx system is in the range of 0.46% to 1,39%. As 
expected, the variability increases as the concentration of the target decreases, although it always 
remains below 5% (Table 13). 
 
 
 
 
 
 
  
Target N Ct Mean Ct Standard deviation CV 
IVS-0032 25 19,95 0,09 0,46 
1:10 IVS-0032 25 23,38 0,14 0,63 
1:100 IVS-0032 25 26,81 0,25 0,95 
1:1000 IVS-0032 25 30,21 0,35 1,16 
1:10000 IVS-0032 25 33,91 0,47 1,39 
Table 13. Reproducibility data 
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5.1.5. ANALYTIC SENSITIVITY 
5.1.5.1. LIMIT OF DETECTION 
Five points (2.6, 1.3, 0.65, 0.26 and 0.13 target / reaction copies) of a serially diluted total RNA 
extracted from a positive human cell line of BCR-ABL p190 translocation were tested in eight 
replicates per dilution point in three consecutive analysis sessions. 
Results, analysed by probit regression, allowed calculating the value of analytic sensitivity (with p = 
0.05) indicated in the graph (Figure 27). 
 
 
 
 
 
 
 
 
 
As can be seen from the chart (Figure	27), you have a 95% probability of detecting 1.58 copies of 
BCR-ABL p190 / reaction on ABI 7500 Fast Dx. 
 
 
 
 
 
 
 
	 	
Figure	27.Probit	graph 
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5.1.5.2. LINEAR RANGE 
The linear range of this assay was determined using a panel of the quantification standard 
“REALQUALITY RQ-BCR-ABL p190 STANDARD”. Specifically, for each target, the points 
corresponding to 5x106, 5x105, 5x104, 5x103, 5x102, 5x10, 5, 2.5 and 1.6 copies of BCR-ABL p190 
/ reaction were amplified in duplicate.  
Considering that a replication of the 1.6 copy / reaction dilution has produced a very different Ct 
result than the other two replicates, the analysis was done by omitting this dilution point. 
 
 
The analysis of the obtained data with linear regression showed that the assay has a linear 
response (R2> 0.99) in the range of 5x106-2.5 copies of the translocation BCR-ABL p190/reaction. 
 
 
 
 
 
 
 
 
  
 BCR-ABL p190 Real time mix ABL Real time mix 
Threshold 0.1 0.1 
Baseline 3/15 3/15 
Slope -3.336 -3.3374 
R2 0.997 0.994 
Table 14. Linear range data 
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5.2. DEVELOPMENT AND VALIDATION OF THE NEW “REALQUALITY RQ-BCR-ABL P210 
ONE-STEP” 
5.2.1. DIAGNOSTIC SPECIFICITY AND SENSITIVITY 
All 26 negative samples analysed were considered suitable for analysis. The assay was able to 
properly identify 26 out of 26 negative samples for BCR-ABL p210 translocation obtaining results 
that agree with the expected. 
All 52 positive samples analyzed were considered suitable for analysis. The assay was able to 
correctly identify 51 of 52 positive for p210BCR-ABL translocation. The device obtained ratio between 
BCR-ABL p210 variant / ABL with orders of magnitude comparable to the expected.  
Specificity and diagnostic sensitivity were defined as follows: 
DIAGNOSTIC SPECIFICITY = Negative results / total negative samples: 
26/26 = 100% 
DIAGNOSTIC SENSITIVITY = Positive results / total positive samples: 
 51/52 = 98% 
 
5.2.2. ACCURACY 
The accuracy was calculated as the percentage of correct results in relation to the total number of 
tested samples (n = 78). The total accuracy of RQ-BCR-ABL p210 One-Step is: 77/78 = 99% 
 
5.2.3. ANALYTICAL SPECIFICITY 
The analytical specificity of the kit is guaranteed by an accurate and specific selection of primers 
and probes and the use of stringent amplification conditions.  
Alignment of primers and probes in the most important databanks showed no non-specific pairing.  
5.2.4. REPRODUCIBILITY 
In order to determine the assay variability (variability among replicates of the same sample in 
different analysis sessions), dilutions of extracted total RNA from positive human cell lines for 
BCR-ABL p210 translocation were tested in five replicates in five consecutive analysis sessions.  
The variability coefficient (CV) of the device was determinate using the cycle threshold value (Ct) 
of each point, dividing the mean value of the standard deviation of Ct (Ct SD) for the mean Ct 
value calculated by the instrument (Ct mean). 
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𝐂𝐕 = 𝐶𝑡 𝑆𝐷 𝑥 100𝐶𝑡 𝑚𝑒𝑎𝑛  
 
  
 
 
N  Ct Mean 
Ct Standard 
deviation CV  
WHO A1 25 31,72 0,34 1,08 
WHO A2 25 29,70 0,14 0,47 
WHO A3 25 26,50 0,08 0,29 
WHO A4 25 23,31 0,13 0,55 
Table 15. Reproducibility data 
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5.2.5. ANALYTIC SENSITIVITY 
5.2.5.1. LIMIT OF DETECTION 
For the calculation of analytical sensitivity, dilutions of WHO positive controls belonging to the 1st 
WHO International Genetic Reference Panel for quantification of BCR-ABL translocation by RQ-
PCR have been used.  
Five points (2.8, 1.4, 0.7, 0.28 and 0.14 target / reaction copies) of a serially diluted total RNA 
extracted from a WHO control were tested in eight replicates per dilution point in an analysis 
session. 
Results, analysed by probit regression, allowed calculating the value of analytic sensitivity (with p = 
0.05) indicated in the graph (Figure 28).  
 
 
 
 
 
 
 
 
 
As can be seen from the chart (Figure 28), you have a 95% probability of detecting 1.63 copies of 
BCR-ABL p210 / reaction on ABI 7500 Fast Dx. 
5.2.5.2. LINEAR RANGE 
The linear range of this assay was determined using a panel of the quantification standard 
“REALQUALITY RQ-BCR-ABL p190 STANDARD”. Specifically, for each target, the points 
corresponding to 5x106, 5x105, 5x104, 5x103, 5x102, 5x10, 5, 2.5 and 1.6 copies of BCR-ABL p210 
/ reaction were amplified in duplicate.  
Considering that a replication of the 1.6 copy / reaction dilution has produced a very different Ct 
result than the other two replicates, the analysis was done by omitting this dilution point. 
 
Figure 28. Probit graph 
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The analysis of the obtained data with linear regression showed that the assay had a linear 
response (R2> 0.99) in the range of 5x106-2.5 copies of the translocation BCR-ABL p210 / 
reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 BCR-ABL p190 Real time mix ABL Real time mix 
Threshold 0.1 0.1 
Baseline 3/15 3/15 
Slope -3.261 -3.329 
R2 0.997 0.994 
Table 16. Linear range data 
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5.3. LABNET: CLINICAL VALIDATION 
5.3.1. COMPARISON OF FINAL DATA IN I.S. OBTAINED WITH “RQ-BCR-ABL P210 ONE-
STEP” AND THE ROUTINELY KIT USED IN THE THREE CENTERS:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The final results of the 30 samples were divided into two groups to fa cilitate its graphic 
representation (Figure 29). In this descriptive analysis there are no substantial differences between 
'routine assays' and RQ-BCR-ABL p210 One-Step. 
RQ-BCR-ABL p210 One Step kit was able to detect a greater number of samples with a MR4.5 
(detectable disease ≤0.0032% BCR-ABLIS) disease level compared to the other routine methods, 
proving to have a high analytical sensitivity. 
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Figure 29. Comparison of final data expressed in International Scale (IS) obtained with the routinely kit 
used in the three centers (Torino, Bologna and Napoli) and "RQ-BCR-ABL p210 One-Step" kit. 
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5.3.2. REPRODUCIBILIY OF FINAL DATA: DETERMINATION OF THE FINAL DATA 
VARIABILITY WITH ROUTINE METHODS COMPARED TO RQ-BCR-ABL P210 ONE-STEP:    
 
 
The reproducibility of the methods was compared by analysing the mean of the standard 
deviations of data obtained with the routine methods for each single sample with those obtained 
with p210 One Step in the three different laboratories (Figure 32).  
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Figure 32. Analysis of reproducibility of the routine methods 
and "RQ-BCR-ABL p210 One-Step" method.   
1 2 3 4 5 6 7 8 9 10 11 12 13 14
0.0000
1.0000
2.0000
3.0000
4.0000
5.0000
Samples
% B
CR
-A
BL
 I.S
.
Reproducibility  Routine
Torino
Bologna
Napoli
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
0.0000
0.0500
0.1000
0.1500
Samples
% B
CR
-A
BL
 I.S
.
Reproducibility  Routine
Torino
Bologna
Napoli
Figure 30. Comparison of final data obtained with routine methods. 
Figure 31. Comparison of final data obtained with "RQ-BCR-ABL p210 One-Step" in each center. 
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5.3.3. ANALYSIS OF AGREEMENT BETWEEN ROUTINE METHODS AND RQ-BCR-ABL P210 
ONE-STEP DEVICE 
 
 
 
This type of analysis allows us to compare a new quantification method with another reference, in 
our case the average of routine methods. The graph correlates the sample concentrations 
(expressed as the mean of the two methods) with the differences between the two methods. 
Most of the values are around zero and within confidence limits, demonstrating that our method is 
comparable to those used in routine. No significant bias is observed since the value 0 is 
compressed to its 95% confidence interval (Figure 34).   
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Figure 34. Bland-Altman plot analysis 
Figure 33. Comparison of the average result of each sample obtained with routine methods and with RQ-BCR-ABL p210 One-Step. 
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5.3.4. QUANTIFICATION OF HOUSEKEEPING GENE: ABL GENE 
 
 
 
 
 
 
 
 
 
 
 
 
Significant differences can be observed in quantification of the ABL gene. These differences 
directly affect inter-laboratory variability.  
 
  
Figure 35. Comparison of the quantification of ABL gene with the different methods 
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5.3.5. REPRODUCIBILITY OF HOUSEKEEPING GENE DETECTION: ABL GENE 
Total ABL gene quantification for each sample was analysed with the different molecular methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There were great differences in ABL quantification with the three routine methods. Homogeneous 
data were obtained with RQ-BCR-ABL p210 One-Step device in the three laboratories. The low 
number of ABL copies for samples 3 is due to a evaporation of the sample during the amplification 
phase at the Bologna center. 
In addition, RQ-BCR-ABL p210 One-Step kit can detect a high average number of ABL copies, 
enabling the analysis of low-level samples such as MR4 or MR 4.5. We can observe in the following 
figures (Figure 39 and Figure 39) how RQ-BCR-ABL p210 One-Step is capable of classificate a 
major number of samples in MR4 or MR 4.5 than routine methods.  
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Figure 37. Analysis of quantification of ABL gene with routine methods 
Figure 37. Analysis of quantification of ABL gene with RQ-BCR-ABL p210 One-Step 
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Figure 39. Quantification of low-level samples (from sample 21 to 
sample 30) with routine methods. 
Figure 39. Quantification of low-level samples (from sample 21 to 
sample 30) with RQ-BCR-ABL p210 One-Step. 
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5.4. INDUSTRIALIZATION PROCESS OF LEUKOPREDICT 
5.4.1. FREEDOM TO OPERATE ANALYSIS 
For the purposes of the Freedom To Operate (FTO) analysis, the technology of LeukoPredict can 
be segmented in two different aspects: 
1) Samples preparation  
2) Samples analysis 
For each of these aspects, we have performed a reconstruction of the patent scenario and a risk 
assessment connected with situations of interference. 
 
5.4.1.1. Samples Preparation 
RECONSTRUCTION OF THE PATENT SCENARIO 
A widest patent scenario, in which it is likely there are third party patents that the technology could 
interfere with, is set on the basis of the International classes (IPC) identified above. 
The patent scenario appears to be characterized by high density. At the date of the present 
analysis, there are not less than 70522 patent families. 
The graph below illustrates (Figure 40), from a subjective point of view, who are the first twenty 
owners of technologies of this group of patents. As seen, there is a significant presence of large 
corporations. However, there is also an important number of public research centers.  
 
 
 
 
 
 
 
 
 
  
Figure 40. Distribution of search results by Assignee 
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The following graph (Figure 41) illustrates the patenting rate for the first twenty owners, starting 
from 1996 (intended as publication year of the applications). The selection of the year is made 
relying on the patent life-length, which is twenty years from priority filing. It is supposed that patents 
published in 1996 had a lifetime at most until 2016. 
As apparent, the patent activity maintains on fair levels, although the years in which it is observed 
an increased acceleration are those comprised in the first decade of the current century. The 
slowdown of the subsequent years in the patenting activity can be explained with the reaching of a 
mature phase within the various patent categories. Furthermore, it must be pointed out that the 
patent applications are published 18 months after filing. Therefore, possible patent applications 
filed during the last 18 months do not appear in these graphs. Considering this, the data related to 
the last two years are inevitably incomplete. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 41. Distribution of search results by 1st publication year/Assignee 
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The following graph (Figure 42) illustrates the trend of the published applications starting from 
1996. As seen, the graph confirms the decreasing trend noted above. 
 
 
 
 
 
 
 
 
The following image (Figure 43) illustrates the geographical distribution of patent publications. This 
image specifies, from a geographical point of view, which are the areas wherein the patent activity 
is greater by publication of applications. It deals with information that visually identifies the most 
important markets, both from a technological point of view and from that of business opportunities. 
In the countries in which the patenting activity is significant, the risk of identifying interfering patents 
is higher. Evidently, the most important markets are USA, Japan, Europe, Australia and Canada. 
 
 
 
 
 
 
  
Figure 42. Distribution of search results by 1st publication year 
Figure 43. Distribution of search results by Publication country (without EP nad WO) 
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The graph below (Figure 44) provides a quick indication of the number of published applications in 
each country, in cumulative terms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 44. Distribution of search results by Publication country 
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LIST OF POTENTIALLY RELEVANT PATENT DOCUMENTS: 
 
N.  
 
Publication 
number 
Title Assignee 
1	 2013-05-24 CN104178424 Red blood cell lysis solution 
and lysis method thereof. 
Surexam Biotech  
 
2 2013-05-10 CN103627638 Composition for lysing red cells, 
red cell lysing reagent and 
application of red cell lysing 
reagent 
BEIJING DONGFANG 
HUAHUI BIOMEDICAL 
TECHNOLOGY  
 
3 2014-10-20 WO2016064887 Red blood cell lysis solution 
 
GEN-PROBE  
 
4 2012-04-18 WO2013158092 Methods and compositions 
for dual extraction of protein and 
nucleic acid 
SYNGENTA 
PARTICIPATIONS 
5 2013-12-30 CN103789298 Erythrocyte lysis buffer and 
application thereof 
SANSURE BIOTECH  
6 2010-05-17 WO2011144304 Universally applicable lysis buffer 
and processing methods for the 
lysis of bodily samples 
CURETIS KURETISU  
 
 
In details, 6 patent documents have been single out (not only issued patents, but also published 
application) that can be potentially relevant. 
As already written, it must be pointed out that the protocol for preparing the samples for the assay 
is not yet definitive and some modifications might still occur. This aspect must be considered in 
ingredients of the RBCs lysis buffer might be modified, thus changing the risk of interference with 
the patent application CN104178424. More details of this patent application are shown below:  
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1. CN104178424 Red blood cell lysis solution and lysis method thereof. 
• Patent Assignee 
SUREXAM BIOTECH  
 
• Inventor 
XU JIASEN 
 LIU ZHIMING 
 WU SHIYANG 
 YANG WEIWEI  
 
• International Patent Classification 
C12N-001/06  
 
• Priority date: 
2013-05-24 
Legal status:  
CN pending 
Abstract: The invention provides a red blood cell lysis solution and a method for lysing red 
blood cells by using the red blood cell lysis solution. The red blood cell lysis solution 
comprises the following components by concentration: 0.1 M to 0.5 M of ammonium 
chloride, 0.001 M to 0.2 M of potassium bicarbonate and 0.001 to 0.05 M of 
ethylenediamine tetraacetic acid or disodium ethylene diamine tetraacetate. The red blood 
cell lysis solution provided by the invention has the advantages of a good red blood cell lysis 
effect, safety to and no toxic and side effect on operators and high lysis efficiency. 
Formaldehyde is used as a fixing agent, and the red blood cell lysis solution is used 
together with other components to realize removal of red blood cells in blood; moreover, the 
solution can be used as a protection agent for a part of non-erythrocyte cells in a blood 
sample for sample transport, thereby overcoming the disadvantage that remaining cell 
components in purified blood cannot be stably preserved in the prior art. 
Independent claims: 
1. A red cell lysate, characterized in, comprising the following component concentrations: 0 . 
1M-0.5M chloride, 0.001M-0.2M potassium bicarbonate, 0.001-0.05 M EDTA or disodium 
EDTA. 
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5.4.1.3. Samples Analysis 
RECONSTRUCTION OF THE PATENT SCENARIO 
The patent scenario in this case appears to be characterized by high density. At the date of the 
present analysis, there are not less than 110511 patent families. 
The graph below (Figure 45) illustrates, from a subjective point of view, who are the first twenty 
owners of technologies of this group of patents. As seen, there are a lot of important companies. 
However, it is important to note the presence of different public research centers.  
 
 
 
 
 
 
 
 
 
 
The following graph (Figure 46) illustrates the patenting rate for the first twenty owners, starting 
from 1996 (intended as publication year of the applications). The selection of the year is made 
basing on the patent life-length, which is twenty years. It is supposed that patents published in 
1996 had a life-time at most until 2016. As seen, the patent activity maintains on fair levels, 
although the years in which it is observed an increased acceleration are those comprised in the 
first five years of the current century. Also in this case, it must be pointed out that the patent 
applications are published 18 months after filing. Considering this, the data related to the last two 
years are incomplete. 
 
 
 
 
Figure 45. Distribution of search resuts by Assignee 
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The following graph (Figure 47) illustrates the trend of the published applications starting from 
1996. As seen, the graph confirms the weak decreasing trend noted above. 
 
 
 
 
 
 
 
 
 
 
  
Figure 46. Distribution of search results by 1st publication year/Assignee 
Figure 47. Distribution of search results by 1st publication year 
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The following image (Figure 48) illustrates the geographical distribution of patent publications. This 
image specifies, from a geographical point of view, which are the areas wherein the patent activity 
is greater by publication of applications. It deals with an information which visually identifies the 
most important markets, both from a technological point of view and from that of business 
opportunities. In the countries in which the patenting activity is significant, the risk of identifying 
interfering patents is higher. As seen, the most important markets are USA, Japan and Europe. 
 
 
 
 
 
 
 
 
 
 
The last graph (Figure 49) provides a quick indication of the number of published applications in 
each country, in cumulative terms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 48. Distribution of search results by Publication country (without EP and WO) 
Figure 49. Distribution of search results by Publication country 
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LIST OF POTENTIALLY RELEVANT PATENT DOCUMENTS: 
 
N. Priority 
date 
Publication 
number 
Title Assignee 
7 2010-11-09 US8921062 Diagnostic and prognostic assays 
based on circulating 
tyrosine kinase activity 
QUEST 
DIAGNOSTICS  
8 2010-11-09 US2015184222 Diagnostic and prognostic assays 
based on circulating tyrosine kinase 
activity 
QUEST 
DIAGNOSTICS  
 
9 2010-10-15 WO2012049329 Method for predicting 
tyrosine kinase inhibitor (tki) 
resistance in patients suffering from 
chronic myelogenous leukemia (cml) 
PAMGENE 
VERENIGING VOOR 
CHRISTELIJK 
HOGER 
ONDERWIJS 
WETEN 
VERENIGING VOOR 
CHRISTELIJK 
HOGER 
ONDERWIJS 
WETENSCHAPPELIJ
K ONDERZOEK EN 
PATIENTENZORG  
 
10 2008-04-11 WO2009125020 Method for profiling drug compounds PAMGENE 
11 2006-10-27 WO2008049930 A method for profiling kinase 
inhibitors 
PAMGENE  
 
12 2009-04-10 WO2010116000 Method for profiling drug compounds 
using protein kinase inhibitors 
PAMGENE  
 
13 2006-03-17 WO2007109571 Methods of predicting and monitoring 
tyrosine kinase inhibitor therapy 
NESTEC 
PROMETHEUS LAB  
 
14 2012-09-13 US20140072516 Methods for detecting enzyme activity 
using fluorescence lifetime imaging 
PURDUE 
RESEARCH 
FOUNDATION 
PURDUE 
UNIVERSITY 
15 2012-02-07 US20130231265 Tyrosine kinase biosensors and 
methods of use 
PURDUE 
RESEARCH 
FOUNDATION 
PURDUE 
UNIVERSITY  
16 2014-05-05 WO2015171395 Degradation Resistant Peptide Based 
Biosensors 
PURDUE 
RESEARCH 
FOUNDATION  
 
 
In details, we singled out 10 patent documents (not only issued patents, but also published 
applications) that can be potentially relevant. In particular, the titles number 7, 8, 9 and 12 can be 
considered as the closest prior art. As far as the title 13 (WO2007109571, US granted) is 
concerned, the claims present in the PCT application could have been potentially relevant. 
Nevertheless, this application was filed on March 17th 2006, and therefore, it has lapsed and it 
cannot be infringed. Furthermore, we consider that the Technology does not infringe the granted 
patent US7908091 (which presents different claims). 
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In more details: 
7. US8921062 Diagnostic and prognostic assays based on circulating tyrosine kinase activity. 
• Patent Assignee 
QUEST DIAGNOSTICS  
 
• Inventor 
YEH CHEN-HSIUNG  
 
• International Patent Classification 
C12Q-001/46 C12Q-001/48 G01N-033/574 
 
• Priority date: 
2010-11-09 
Legal status:  
US granted  
Abstract: Provided herein are methods for the diagnosis, prognosis, or management of 
diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. 
Further provided are methods of predicting response to therapy in certain populations of 
cancer patients by contacting an acellular body fluid sample from a patient with a test agent, 
such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on 
tyrosine kinase activity in the sample. 
Independent claims: 
1. A method for predicting the response of a patient with a BCR-ABL1-positive leukemia to 
therapy with a BCR-ABL1 kinase inhibitor, the method comprising: 
(a) measuring a first level of circulating tyrosine kinase (cTK) activity in a first sample of an 
acellular body fluid from a patient wherein the acellular body fluid is selected from the group 
consisting of plasma and serum, and wherein the measuring comprises contacting the 
plasma or serum with one or more tyrosine kinase (TK) substrates and measuring the 
phosphorylation of the one or more substrates by cTKs; 
(b) contacting a second sample of plasma or serum from the patient with an effective 
amount of one or more BCR-ABL1 kinase inhibitors; 
(c) measuring a second level of cTK activity in the second plasma or serum sample after it 
has been contacted with the one or more BCR-ABL1 kinase inhibitors, wherein the 
measuring comprises contacting the plasma or serum with one or more tyrosine kinase (TK) 
substrates and measuring the phosphorylation of the one or more substrates by cTKs; and 
(d) comparing the first level of cTK activity to the second level of cTK activity, wherein a 
decrease between the first level and the second level indicates that the patient is a potential 
responder to therapy with the one or more BCR-ABL1 kinase inhibitors, and wherein no 
change between the first level and the second level indicates that the patient is potentially 
not a responder to therapy with the one or more BCR-ABL1 kinase inhibitors. 
 
 
8. US2015184222 Diagnostic and prognostic assays based on circulating tyrosine kinase activity. 
• Patent Assignee 
QUEST DIAGNOSTICS  
 
• Inventor 
YEH CHEN-HSIUNG  
 
• International Patent Classification 
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C12Q-001/48  
 
• Priority date: 
2010-11-09 
Legal status: 
US pending 
Abstract: Provided herein are methods for the diagnosis, prognosis, or management of 
diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. 
Further provided are methods of predicting response to therapy in certain populations of 
cancer patients by contacting an acellular body fluid sample from a patient with a test agent, 
such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine 
kinase activity in the sample. 
Independent claims: 
1. A method for identifying the presence or absence of a neoplastic disease in a subject, the 
method comprising: (a) measuring the level of circulating tyrosine kinase (cTK) activity in an 
acellular body fluid sample from a human subject suspected of having a neoplastic disease; 
and  
(b) identifying the subject as: (i) having a neoplastic disease when the level of cTK activity in 
the sample differs from a reference cTK activity level; or  
(ii) not having a neoplastic disease when the level of cTK activity in the sample does not differ 
from a reference cTK activity level. 
21. A method for determining a prognosis for a patient having a proliferative hematological 
disorder, comprising: (a) measuring a first level of cTK activity in a first acellular body fluid 
sample collected at a first time point from a patient;  
(b) measuring a second level of cTK activity in a second acellular body fluid sample collected 
at a second time point from the patient;  
(c) comparing the first level to the second level; and  
(d) identifying the subject as: (i) having a good prognosis when there is a decrease between 
the first level and the second level; and  
(ii) having a poor prognosis when there is an increase between the first level and the second 
level or a lack of a decrease between the first level and the second level. 
 
9	.	WO2012049329 Method for predicting tyrosine kinase inhibitor (TKI) resistance in patients 
suffering from chronic myelogenous leukemia (CML). 
• Patent Assignee 
PAMGENE VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETEN VERENIGING 
VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN 
PATIENTENZORG  
 
• Inventor 
BOENDER PIETER JACOB 
VAN DEN BERG ADRIANA 
RUIJTENBEEK ROBBY 
JANSSEN JEROEN JOHANNES WILHELMUS MARIA 
OSSENKOPPELE GERRIT JOHAN  
 
• International Patent Classification 
C12Q-001/48 G01N-033/574 
 
• Priority date: 
2010-10-15 
Legal status:  
US pending  
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EP lapsed 
Abstract: The present invention relates to a method for determining or predicting the response 
of a patient diagnosed with chronic myelogenous leukaemia (CML) to treatment with a tyrosine 
kinase inhibitor. More specifically, the present invention provides methods which measure 
kinase activity by studying phosphorylation levels and profiles and inhibitions thereby 
diagnosing CML patients resistant to treatment with Imatinib. 
Independent claims: 
1. A method for predicting the response of a patient diagnosed with chronic myelogenous 
leukaemia (CML), to a tyrosine kinase inhibitor (TKI), comprising the steps of:  
(a) measuring the kinase activity of a sample, obtained from said patient diagnosed with CML, 
by contacting said sample with immobilized protein kinase substrates, thereby providing a 
phosphorylation profile of said sample, said phosphorylation profile comprising the 
phosphorylation levels of phosphorylation sites present in at least 10 peptide markers as listed 
in Table 1 ; and,  
(b) determining from said phosphorylation profile the response of said patient to said TKI.  
10. A method for diagnosing CML for a patient, wherein the kinase activity of a sample, 
obtained from said patient, is measured, wherein said kinase activity measurement provides 
phosphorylation profiles of said sample thereby diagnosing CML for said patient. 
14. A method for predicting the discontinuation of tyrosine kinase inhibitor treatment to patients 
diagnosed with CML but who are unware of being cured and continue to receive tyrosine 
kinase inhibitor treatment, comprising the steps of:  
(a) measuring the kinase activity of a sample, obtained from said patient diagnosed with CML, 
who continues to receive tyrosine kinase inhibitor (TKI) treatment, by contacting said sample 
with immobilized protein kinase substrates, thereby providing a phosphorylation profile of said 
sample, said phosphorylation profile comprising the phosphorylation levels of phosphorylation 
sites present in at least 10 peptide markers as listed in Table 1 ; and, (b) determining from said 
phosphorylation profile the disease free status of said patient.  
Table 1: SEQ ID NO Name Sequence (N terminus to C terminus) 
1 ACHD 383 395 YISKAEEYFLLKSG 
2 AMPE 5 17 EREGSKRYCIQTKG 
3 ANXA1 14 26 IENEEQEYVQTVKG 
4 ANXA2 17 29 HSTPPSAYGSVKAG 
5 B3AT 39 51 TEATATDYHTTSHG 
6 CALM 93 105 FDKDGNGYISAAEG 
7 CALM 95 107 KDGNGYISAAELRG 
8 CBL 693 705 EGEEDTEYMTPSSG 
9 CD3Z 116 128 KDKMAEAYSEIGMG 
10 CD79A 181 193 EYEDENLYEGLNLG 
1 1 CDK2 8 20 EKIGEGTYGWYKG 
12 CDK3 12 26 EGTYG WYKA KN R ETG 
13 CTNB1 79 91 VADI DGQYAMTRA 
14 DCX 109 121 GIVYAVSSDRFRSG 
15 DDR1 506 518 LLLSNPAYRLLLAG 
16 DYR1A 212 224 KHDTEMKYYIVHLG 
17 DYR1A 312 324 CQLGQRIYQYIQSG 
18 EFS 246 258 GGTDEGIYDVPLLG 
19 EGFR 1062 1074 EDSFLQRYSSDPT 
20 EGFR 1103 1 115 GSVQNPVYHNQPLG 
21 EGFR 1 118 1130 APSRDPHYQDPHS 
22 EGFR 1165 1 177 ISLDNPDYQQDFFG 
23 EGFR 1190 1202 STAENAEYLRVAPG 
24 EGFR 862 874 LGAEEKEYHAEGG 
25 EGFR 908 920 MTFGSKPYDGIPA 
26 ENOG 37 49 SGASTGIYEALELG 
27 EPHA1 774 786 LDDFDGTYETQGGG 
28 EPHA2 581 593 QLKPLKTYVDPHTG SEQ ID NO Name Sequence (N terminus to C 
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terminus) 
29 EPHA2 765 777 EDDPEATYTTSGGG 
30 EPHA4 589 601 LNQGVRTYVDPFTG 
31 EPHA4 921 933 QAIKMDRYKDNFTG 
32 EPHA7 607 619 TYIDPETYEDPNRG 
33 EPHB1 771 783 DDTSDPTYTSSLGG 
34 EPHB1 921 933 SAIKMVQYRDSFLG 
35 EPHB4 583 595 IGHGTKVYIDPFTG 
36 EPOR 361 373 SEHAQDTYLVLDKG 
37 EPOR 419 431 ASAASFEYTI LDPG 
38 ERBB2 1241 1253 PTAENPEYLGLDVG 
39 ERBB2 870 882 LDIDETEYHADGG 
40 ERBB4 1181 1 193 QALDNPEYHNASN 
41 FABPH 13 25 DSKNFDDYMKSLGG 
42 FAK1 569 581 RYMEDSTYYKASKG 
43 FAK2 572 584 RYI EDEDYYKASVG 
44 FER 707 719 RQEDGGVYSSSGLG 
45 FES 706 718 REEADGVYAASGGG 
46 FGFR2 762 774 TLTTNEEYLDLSQG 
47 FGFR3 641 653 DVHNLDYYKKTTNG 
48 FGFR3 753 765 TVTSTDEYLDLSAG 
49 FRK 380 392 KVDNEDIYESRHEG 
50 INSR 1348 1360 SLGFKRSYEEHIPG 
51 INSR 992 1004 YASSN PEYLSASDG 
52 JAK1 1015 1027 AIETDKEYYTVKDG 
53 K2C6B 53 65 GAGFGSRSLYGLGG 
54 KSYK 518 530 ALRADENYYKAQTG 
55 LAT 194 206 MESIDDYVNVPESG 
56 LAT 249 261 EEGAPDYENLQELG 
57 LCK 387 399 RLIEDNEYTAREGG 
58 MBP 198 210 ARTAHYGSLPQKSG 
59 MBP 259 271 FGYGGRASDYKSAG 
60 MBP 263 275 GRASDYKSAHKGFG 
61 MET 1227 1239 RDMYDKEYYSVHNG 
62 MK01 180 192 HTGFLTEYVATRW 
63 MK01 198 210 IMLNSKGYTKSID 
64 MK07 21 1 223 AEHQYFMTEYVATG 
65 MK10 216 228 TSFMMTPYWTRYG 
66 MK12 178 190 ADSEMTGYVVTRWG 
67 MK14 173 185 RHTDDEMTGYVATG 
68 NTRK1 489 501 HIIENPQYFSDACG 
69 NTRK2 509 521 PVI EN PQYFGITNG 
70 P85A 600 612 NENTEDQYSLVEDG 
71 PAXI 1 11 123 VGEEEHVYSFPNKG 
72 PAXI 24 36 FLSEETPYSYPTGG 
73 PDPK1 2 14 ARTTSQLYDAVPI 
74 PDPK1 369 381 DEDCYGNYDNLLS 
75 PECA1 706 718 KKDTETVYSEVRKG 
76 PERI 458 470 QRSELDKSSAHSYG 
77 PGFRB 1002 1014 LDTSSVLYTAVQPG 
78 PGFRB 572 584 VSSDGHEYIYVDPG 
79 PGFRB 709 721 RPPSAELYSNALPG SEQ ID NO Name Sequence (N terminus to C 
terminus) 
80 PGFRB 768 780 SSNYMAPYDNYVPG 
81 PGFRB 771 783 YMAPYDNYVPSAPG 
82 PLCG1 1246 1258 EGSFESRYQQPFEG 
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83 PLCG1 764 776 IGTAEPDYGALYEG 
84 PLCG1 776 788 EGRNPGFYVEANP 
85 PP2AB 297 309 EPHVTRRTPDYFLG 
86 PRRX2 202 214 WTASSPYSTVPPYG 
87 RASA1 453 465 TVDGKEI YNTI RRG 
88 RBL2 99 11 1 VPTVSKGTVEGNYG 
89 RET 1022 1034 TPSDSLIYDDGLSG 
90 RET 680 692 AQAFPVSYSSSGAG 
91 RON 1346 1358 SALLGDHYVQLPAG 
92 RON 1353 1365 YVQLPATYMNLGPG 
93 SRC8 CHICK 470 482 VSQREAEYEPETVG 
94 SRC8 CHICK 476 488 EYEPETVYEVAGAG 
95 SRC8 CHICK 492 504 YQAEENTYDEYENG 
96 STA5A 687 699 LAKAVDGYVKPQIG 
97 STAT1 694 706 DGPKGTGYIKTELG 
98 STAT3 698 710 DPGSAAPYLKTKFG 
99 STAT4 686 698 TERGDKGYVPSVFG 
100 STAT4 714 726 PSDLLPMSPSVYAG 
101 TEC 512 524 RYFLDDQYTSSSGG 
102 TYR03 679 691 Kl YSG DYYRQGCAG 
103 VGFR1 1049 1061 KNPDYVRKGDTRL 
104 VGFR2 1052 1064 DIYKDPDYVRKGD 
105 VGFR3 1061 1073 DIYKDPDYVRKGSG 
106 VINC 815 827 KSFLDSGYRI LGAG 
107 ZAP70 485 497 ALGADDSYYTARSG 
108 ZBT16 621 633 LRTHNGASPYQCTG 
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12. WO2010116000 Method for profiling drug compounds using protein kinase inhibitors. 
• Patent Assignee 
PAMGENE  
 
• Inventor 
RUIJTENBEEK ROBBY 
 
• International Patent Classification 
C40B-030/04 G01N-033/50 
 
• Priority date: 
2009-04-10 
Legal status: 
EP granted 
US pending 
WO2010116000 
Abstract: The present invention relates to a method for determining the effect of a drug on the 
kinase activity in a sample or predicting the response of a patient to a drug, wherein the kinase 
activity of a sample in the presence of a protein kinase inhibitor is measured, said protein 
kinase inhibitor mimicking the effect of said drug compound on the kinase activity in said 
sample. 
Independent claims: 
1. A method for determining the effect of a drug on the kinase activity in a cell lysate sample, 
comprising the steps of:  
(a) measuring the kinase activity of said cell lysate sample, in the presence and in the absence 
of a protein kinase inhibitor, thereby providing a phosphorylation profile of said cell lysate 
sample in the presence of a protein kinase inhibitor and a phosphorylation profile of said cell 
lysate sample in the absence of a protein kinase inhibitor; and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor inhibits the kinase domain of a surface receptor targeted by said 
drug thereby mimicking the effect of said drug on the kinase activity in said cell lysate sample. 
2. A method for determining the effect of a drug on the kinase activity in a cell lysate sample, 
comprising the steps of:  
(a) measuring the kinase activity of said cell lysate sample, in the presence and in the absence 
of a protein kinase inhibitor, thereby providing a phosphorylation profile of said cell lysate 
sample in the presence of a protein kinase inhibitor and a phosphorylation profile of said 
sample cell lysate in the absence of a protein kinase inhibitor; and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor inhibits proteins associated with the signal transduction pathway of 
a surface receptor targeted by said drug thereby mimicking the effect of said drug on the drug 
targeted signal transduction pathway in said cell lysate sample. 
3. A method for predicting the resistance of a patient to a drug, comprising the steps of:  
(a) measuring the kinase activity of a cell lysate sample, obtained from said patient, in the 
presence and in the absence of a protein kinase inhibitor, thereby providing a phosphorylation 
profile of said cell lysate sample in the presence of a protein kinase inhibitor and a 
phosphorylation profile of said cell lysate sample in the absence of a protein kinase inhibitor; 
and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor acts towards proteins of one or more alternative signal 
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transduction pathways causing tumor growth, thereby reporting on the activity of alternative 
signal transduction pathways causing tumor growth which are not affected by the drug, thereby 
causing resistance. 
4. A method for predicting the resistance of a patient to a drug, comprising the steps of:  
(a) measuring the kinase activity of a cell lysate sample, obtained from said patient, in the 
presence and in the absence of a protein kinase inhibitor, thereby providing a phosphorylation 
profile of said cell lysate sample in the presence of a protein kinase inhibitor and a 
phosphorylation profile of said cell lysate sample in the absence of a protein kinase inhibitor; 
and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor inhibits proteins of a signal transduction pathway not targeted by 
said drug, thereby reporting on the activity of a signal transduction pathway which is not 
affected by said drug, thereby reporting resistance. 
EP2417452 B1 
Abstract: The present invention relates to a method for determining the effect of a drug on the 
kinase activity in a sample or predicting the response of a patient to a drug, wherein the kinase 
activity of a sample in the presence of a protein kinase inhibitor is measured, said protein 
kinase inhibitor mimicking the effect of said drug compound on the kinase activity in said 
sample. 
Independent claims: 
1. A method for determining the effect of a drug on the kinase activity in a cell lysate sample, 
comprising the steps of:  
(a) measuring the kinase activity of said cell lysate sample, in the presence and in the absence 
of a protein kinase inhibitor, thereby providing a phosphorylation profile of said cell lysate 
sample in the presence of a protein kinase inhibitor and a phosphorylation profile of said cell 
lysate sample in the absence of a protein kinase inhibitor; and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor inhibits the kinase domain of a surface receptor targeted by said 
drug thereby mimicking the effect of said drug on the kinase activity in said cell lysate sample. 
• 2. A method for determining the effect of a drug on the kinase activity in a cell lysate sample, 
comprising the steps of:  
(a) measuring the kinase activity of said cell lysate sample, in the presence and in the absence 
of a protein kinase inhibitor, thereby providing a phosphorylation profile of said cell lysate 
sample in the presence of a protein kinase inhibitor and a phosphorylation profile of said 
sample cell lysate in the absence of a protein kinase inhibitor; and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor inhibits proteins associated with the signal transduction pathway of 
a surface receptor targeted by said drug thereby mimicking the effect of said drug on the drug 
targeted signal transduction pathway in said cell lysate sample. 
• 3. A method for predicting the resistance of a patient to a drug, comprising the steps of:  
(a) measuring the kinase activity of a cell lysate sample, obtained from said patient, in the 
presence and in the absence of a protein kinase inhibitor, thereby providing a phosphorylation 
profile of said cell lysate sample in the presence of a protein kinase inhibitor and a 
phosphorylation profile of said cell lysate sample in the absence of a protein kinase inhibitor; 
and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor acts towards proteins of one or more alternative signal transduction 
pathways causing tumor growth, thereby reporting on the activity of alternative signal 
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transduction pathways causing tumor growth which are not affected by the drug, thereby 
causing resistance. 
• 4. A method for predicting the resistance of a patient to a drug, comprising the steps of:  
(a) measuring the kinase activity of a cell lysate sample, obtained from said patient, in the 
presence and in the absence of a protein kinase inhibitor, thereby providing a phosphorylation 
profile of said cell lysate sample in the presence of a protein kinase inhibitor and a 
phosphorylation profile of said cell lysate sample in the absence of a protein kinase inhibitor; 
and, 
(b) determining from said phosphorylation profiles in the presence and in the absence of a 
protein kinase inhibitor the differential phosphorylation profile, said differential phosphorylation 
profile indicating the effect of said drug on the kinase activity in said cell lysate sample, wherein 
said protein kinase inhibitor inhibits proteins of a signal transduction pathway not targeted by 
said drug, thereby reporting on the activity of a signal transduction pathway which is not 
affected by said drug, thereby reporting resistance. 
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5.4.2. COST-EFFECTIVENESS ANALYSIS 
5.4.2.1. Model validation 
The model has been validated in line with the recommendation of good research practice in 
modeling. 200 Validation of the model was limited at internal and cross-validation. 
5.4.2.2. Internal validation 
Internal model validation was done in two steps: inputs verification procedure and extreme value 
analysis procedure. As a part of inputs verification procedure, each model input was checked with 
the primary source. Extreme value analysis procedure use sensitivity analysis by incorporating 
extreme or null values of parameters inputs to access whether the results are moving in the 
expected direction. All identified “bugs” were successfully corrected. 
5.4.2.3. Cross-validation 
Decision analytic model from this analysis was cross-validated with Padula et al. 186model, as the 
only published model that uses EMR as a surrogate endpoint in the modeling of survival and 
transition probabilities. Cross-validation was limited to the QALY calculated by the models in the 
standard of care arm for the base-case analysis and scenario analysis. Results are presented in 
Table 13. 
Table 17. Cross-model validation of 5-years results in standard treatments arms. 
Model 
Standard of care arm – five years’ results 
Base-case* QALY gained Scenario analysis** QALY gained 
LeukoPredict model 4.02 3.80 
Padula et al. 186 3.98 3.82 
Legend: *First-line treatment real-world settings, **First-line treatment, guidelines recommendations, QALY – quality 
adjusted life years 
 
Results are presented at the five years, as a time horizon used in the Padula et al.  186 analysis. 
Results can be considered as a similar, and they were calculated by models using different 
methods. Namely, Padula et al.  186 were conducted the patient-level simulation, while this analysis 
is used cohort simulations. The main data sources for the EMR as a surrogate endpoint were 
different in the analyses, while this analysis used Neelakantan et al. 178study, Padula et al.  186 were 
used a meta-analysis of several published clinical trial results.  
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5.4.2.4. Base-case results 
Threshold analysis results are presented in Figure 50. Due to the evident cost-saving effect at any 
threshold the “Optimal Operating Point” was selected based on the threshold linked to the 
sensitivity/specificity pair leading to the highest QALY gained Figure 51.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, the threshold at 0,86 linked to the 94% sensitivity and 83% specificity was selected as 
an “Optimal Operating Point” leading to the biggest cost savings and highest QALY gain. 
As already explained in the Methods section in the base-case analysis patients receive first-line 
treatment in line with real-world settings (33.33% per tyrosine kinases inhibitor, including Imatinib, 
Dasatinib, and Nilotinib). Results are presented in Table 18.  
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Figure 50. Changes in ICER by changing test positivity threshold 
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Figure 51. Changes in QALY gained by changing test positivity threshold 
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Table 18. Base-case results of cost-utility analysis 
 
Cost, £ ∆ cost, £ LYG, years ∆ LYG QALY ∆ QALY 
ICER, 
£/QALY 
Standard of care 196577  6,53  5,72   
Standard of care 
plus LeukoPredict 196277 -300 6,63 0,10 5,89 0,17 Dominates 
Legend: LYG – life years gained, QALY – quality adjusted life years. ICER – incremental cost-effectiveness ratio. 
 
Within standard approach in quantifying uncertainty in decision analytic models, a one-way 
sensitivity analysis (Figure 52) was conducted to address parameters uncertainty. Parameters with 
the biggest impact on the ICER were drug cost for first and second line treatments. 
 
 
 
  
Figure 52. Tornado diagram -- base-case analysis 
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5.4.2.5. Scenario analysis results 
To properly address different possible alternatives and relevant clinical scenarios which one-way 
sensitivity analyses were not addressed two additional scenario analysis were conducted. 
Scenario analysis 1 
In the scenario analysis, 1 patients receive first-line treatment with Imatinib (100% Imatinib). 
Results are presented in Table 19 
Table 19. Cost-utility results scenario analysis 1 
 Cost, £ ∆ cost, £ 
LYG, 
years ∆ LYG QALY ∆ QALY 
ICER, 
£/QALY 
Standard of care 
 
159556 
 
 6,31  5,35   
Standard of care 
plus LeukoPredict 164486 4930 6,48 0,17 5,66 0,31 15865 
Legend: LYG – life years gained, QALY – quality adjusted life years. ICER – incremental cost-effectiveness ratio. 
	
 Figure 53. Tornado diagram -- scenario analysis 1 
In the scenario analysis 1, the most sensitive parameters ( Figure 53) are still drug costs and 
expectably drug cost for the first line treatment for Dasatinib and Nilotinib which will be used 
instead of the Imatinib in resistance patients in LeukoPredict arm. Consequently, a fraction of the 
intolerant patients starts to play a major role due to the biggest probability of drug resistance for the 
Imatinib.   
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Scenario analysis 2 
In the scenario analysis 2 patients receive first-line treatment in line with European LeukemiaNet 
recommendations (100% Imatinib) but cost decreases of Imatinib due to the generic entry was 
modeled, with prioritizing patients to receive Imatinib in the first line treatment due to the lower 
costs. Results are presented in Table 20 
 
Table 20. Cost-utility results analysis 2 
 Cost, £ ∆ cost, £ 
LYG, 
years ∆ LYG QALY ∆ QALY 
ICER, 
£/QALY 
Standard of care 95794  6,31  5,35   
Standard of care 
plus LeukoPredict 98084 2290 6,48 0,17 5,66 0,31 7371 
Legend: LYG – life years gained, QALY – quality adjusted life years. ICER – incremental cost-effectiveness ratio. 
 
 
 
Results of the one-way sensitivity analysis presented at Figure 54 revealed same cost parameters 
as a most sensitive on cost variation in line with sensitivity analysis for base-case and scenario 
analysis 1.   
Figure 54. Tornado diagram -- scenario analysis 2 
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5.4.2.6. Limitations of the analysis 
Decision analytic modeling has an in-built limitation of simulating reality. In the analysis, multiple 
sources of information are collected together, and they might lack proper correspondence. In 
general, the main limitation of the early health technology assessment, including this analysis, is 
that empirical data to inform decision analytic model are limited or immature and incomplete, and 
therefore uncertainty regarding results is always of greater extent in comparison with the standard 
economic evaluations. 
Specifically for this research question there are several important limitations, which should be 
considered when interpreting the results of this study 
• The diagnostic accuracy data regarding LeukoPredict test was estimated from the 
preclinical studies which will are not necessarily correspond to clinical performance. The 
data cost of test itself as well as a resource used is based on the assumption in the 
personal communication with test developers. 
• Cohort’s starting age was 50 years of life according to the main available data source used 
in the analysis, but according to the data from Hematological Malignancy Research 
Network (HMRN) reported in the HTA report by Pavey et al. 187 mean age of the diagnosis 
of CML in the UK is a 57 years of life.  
• Survival after stem cell transplantation was informed by the real-world data from 
Hammersmith Hospital, London, between 2000 and 2010 187with patients with median age 
of 60 years of life. This deviation from the starting age of modeled cohort should not affect 
overall modeled survival to a great extent due to the small fraction of the cohort receiving 
stem cell transplantation. On the other hand, those were the only available data regarding 
stem cell transplantation as a third line therapy in the treatment of the CML patients in the 
UK.  
• The model was not including any patient categorizations by commonly used risk scores 
categories at the beginning of the treatment (e.g. Sokal, EUTOS, Hasford).  
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6. DISCUSSION 
The role of BCR-ABL rearrangement in the development and pathogenesis of CML is well 
documented. In fact, the formation of BCR-ABL tyrosinkinase protein plays a major role in the 
pathogenesis of CML, and it is able to influence biological events such as uncontrolled cell 
proliferation, inhibition of apoptosis, and reduction of cellular adhesion.  
Currently, TKI therapy has proven to be effective, with high overall survival rates and event-free 
survival rates in most patients. However, there is a percentage of patients who do not have an 
optimal response to therapy, or who, after an early effective period, develops resistance to 
treatment. The problem of non-responders should not to be underestimated, both regarding the 
patient’s health and the healthcare costs involved. 
The response to TKI is the most significant prognostic value. Defining the disease level through 
regular BCR-ABL transcript quantification is the most effective method for measuring the 
pharmacological effect of TKI, with the aim of maintaining or modifying the therapeutic plan 
according to these results. The monitoring of therapeutic response has become necessary and 
routinely. It can be performed at the molecular or cytogenetic level, or both. 
Since disease levels are expressed as the ratio between BCR-ABL transcripts and control gene 
quantity, high sensitivity and measuring accuracy of these are required, thus as small variations 
could lead to the inclusion of a patient in a level of disease to which it doesn’t really belong to.  
The method used for BCR-ABL quantification has evolved over time. At first it was only possible to 
identify the presence or absence of transcripts, either with classical PCR or with 2-step ‘nested’ 
amplification with internal primers to improve sensitivity. 
To date, thanks to the use of qRT-PCR Real-Time, not only it is possible to identify the BCR-ABL 
transcripts, but also its quantification is very fast and sensitive, capable of detecting up to 0.001% 
BCR-ABL / ABL. In addition, small steps towards the automation of the process, such as the 
introduction of One-Step technology, help to reduce the amount of time it takes to analyse it, 
eliminating steps and avoiding errors and contaminations of the sample. 
In this direction, the company DOTT. DINO PALADIN has developed and validated two new kits 
(RQ-BCR-ABL p190 One-Step and RQ-BCR-ABL p210 One-Step) based on the qRT-PCR Real-
Time One-Step method for CML monitoring. Both devices allow, through One-step technology, the 
retrotranscription and amplification directly from RNA of patient in a one unique step. 
The RQ-BCR-ABL p210 One-Step device has demonstrated a diagnostic specificity of 100%. To 
calculate it, 26 negative RNA for M-bcr b2a2 and b3a2 (p210BCR-ABL) were tested with the RQ-BCR-
ABL p210 One-Step, without getting any sign of positivity for any of the samples. The kit has 
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obtained a diagnostic sensitivity of 98%, since it has detected 51 positives samples out of a total of 
52.  
The non-concordant sample in question was tested three times with the device, in a first session in 
double test, then in the second session in single test. 
During these sessions, 2 out of 3 replicates were undetermined for the target while one replicate 
was positive, though with a very low signal. The percentage ratio of first session has been 
consistent, but the standard of ABL was unsuitable. In the second session, however, this sample 
has identified as negative, which is why it isn’t in agreement with the expected result. There is the 
possibility of degradation of the sample or, most likely, the patient was in remission of the disease 
(MR4.5). 
The values obtained show a robust and reliable device for therapeutic monitoring according to 
reproducibility and linearity. In addition, an analytical sensitivity of 1.63 copies p210BCR-ABL/ABL 
makes it possible to quantify those samples with lower levels of disease.  
Moreover, the RQ-BCR-ABL p210 One-Step kit has demonstrated a high specificity at when 
identifying and quantifying only the M-bcr b2a2 e b3a2 (p210BCR-ABL) translocation, as resulted by 
the analytical specificity tests performed during the kit validation. Such tests are carried out with 
the aim of detecting a possible cross-reactivity. A total of 10 ALL patients positives for p190BCR-ABL 
translocation were tested, finding no positivity result in the analysis with the RQ-BCR-ABL p210 
One-Step kit.  
The need to develop a kit for detection and quantification of p190BCR-ABL variant is related to the 
presence of a small percentage of patients with CML who present these transcripts43,44, instead of 
the characteristic p210BCR-ABL, and to its use in the therapeutic monitoring of acute lymphoblastic 
leukemia (ALL), where the presence of p190BCR-ABL is most characteristic. Identifying these patients 
as early as possible is very important as explained by Dushyant V. et al. “p190BCR-ABL CML is 
associated with an inferior outcome to therapy with TKI. These patients need to be identified as 
high-risk patients.” 43  
RQ-BCR-ABL p190 One-Step kit has been shown to have a great high diagnostic sensitivity and 
specificity (100% in both cases) and to be very reproducible, with variability in results below 5%. 
The kit has shown a limit of detection of 1.58 copies p190BCR-ABL/reaction, succeeding in identifying 
samples with a very low level of disease. In addition, the assay has been shown to be linear in a 
wide range, 5x106-2,5 copies/reaction, providing robustness in the quantification of samples with 
different disease loads.  
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The values obtained for the performance of both devices fully meet the requirements for an in vitro 
diagnostic device. The assay was therefore suitable for commercialization and use in diagnostic 
practice such as CE-IVD. 
As explained above in clinical practice, two measurements are performed for each test sample: an 
estimate of the amount of BCR-ABL transcript as a measure of leukemic load in the patient, and an 
estimate of the amount of control gene as a measure of the quantity and quality of cDNA contained 
in the sample. The number of control gene obtained for samples that are negative to translocation 
provides an indication of sensitivity that can excludes residual disease for that particular patient. 
Studies have shown that the amplification of targets with highly differing concentrations in the 
same reaction may lead to a strong competition, which severely impedes amplification of the lower 
concentrated target and results in false-negatives. For this reason, the amplification of ABL and 
BCR-ABL p210 cDNA is performed in separate reactions. 
Both kits have the design of standard controls for the quantification of the samples in common. A 
single plasmid, including both the target region (m-bcr region for RQ-BCR-ABL p190 One-Step kit 
and M-bcr region for RQ-BCR-ABL p210 One-Step kit) and the control gene region (ABL) was 
created. They were subsequently calibrated with certified material with a known concentration. For 
quantification standard calibration, IRMM ERM-AD623 BCR-ABL1 was used, that allows 
quantification of M-bcr transcripts in the sample and normalization to the expression of the 
housekeeping gene ABL. We also used IVS panel,	 which is a panel with different known 
concentrations of ABL. 
The use of a single plasmid as a control for BCR-ABL transcript quantification is advantageous for 
several reasons. On one hand, it eliminates possible errors in the final data due to a possible 
degradation of one of the two plasmids, which would cause a sub-quantification of one of the two 
(BCR-ABL or ABL). With the use of a single plasmid, any plasmid degradation errors happen for 
both targets, minimizing the damage in the final quantification. In addition, its use speeds up and 
simplifies the procedure. Moreover, choosing plasmids that contain both target and control 
sequences are recommended by several studies83,201 to limit the variability of the assay. 
The existence of variations in the quantification of BCR-ABL transcripts according to the method 
used has led to standardization of results by applying the International Scale. (IS). To be able to 
express quantification data in IS, a conversion factor is required. This conversion factor can be 
obtained by testing reference material the 1st WHO International Genetic Reference Panel for 
quantification of BCR-ABL translocation (b3a2), which includes 4 points at different known 
concentrations of BCR-ABL/control gene (ABL, BCR or GUSB). 
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With the aim of harmonizing inter-center variations in mind, a European network has been created 
by laboratories and reference centers to evaluate and control the methods used in diagnostics. 
This organization performs periodic inspections in the various reference laboratories, in order to 
ensure the uniformity of all results. 
In Italy these functions are carried out by LabNet network. This network links Italian haematology 
physicians who treat CML with laboratories where molecular tests are performed. Today, LabNet 
CML includes 56 laboratories, standardized and subjected to quality controls. Each of them works 
as a reference for one or more hematology centers. 
The RQ-BCR-ABL p210 One-Step has undergone a clinical validation within this network, 
specifically in three different reference centers, with the aim of being validated as a certified 
method for CML monitoring. 
The comparison between our method and the methods used in diagnostic routine in each 
laboratory was satisfactory. The statistical analysis used to compare the final results was the 
Bland-Altman method. This type of analysis allows us to juxtapose a new quantification method 
(RQ-BCR-ABL p210 One-Step) with another reference, in our case the average of routine 
methods. The graph (Figure 34) correlates the sample concentrations (expressed as the mean of 
the two methods) with the differences between the two methods. 
Most of the values are around zero and within confidence limits, demonstrating that our method is 
comparable to those used in routine. No significant bias is observed since the value 0 is 
compressed to its 95% confidence interval.  
The presence of two values outside the confidence limits (samples 5 and 6) is due to the data 
obtained with the routine method used in Bologna. The results obtained with Bologna’s routine 
method for the two samples were completely different from those obtained with the other reference 
methods. Therefore, these two values do not depend on the data obtained with RQ-BCR-ABL p210 
One-Step.  
The reproducibility of methods was compared by analysing the mean of standard deviations of 
data obtained with the routine methods for each single sample with those obtained with RQ-BCR-
ABL p210 One-Step in the three different laboratories. 
The results show that the RQ-BCR-ABL p210 One-Step device produced very similar values for 
the same sample in different laboratories where the analyses were performed; whereas the results 
of routine systems of individual labs showed less homogeneous data with standard deviations 
more marked than those of RQ-BCR-ABL p210 One-Step device.   
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Quantification of the ABL transcript not only allows normalization of the BCR-ABL fusion transcript, 
but also permits the user to detect reaction inhibitors and to assess the quality of the RNA extract. 
This is a valuable tool for identifying false-negative results. 
Given the importance of a correct measurement of the control gene, we have also compared the 
results of ABL quantification. 
The average number of ABL copies obtained in three centers with the RQ-BCR-ABL p210 One-
Step kit varies from 70,000 to 76,000, an average to high number that allows for low levels of 
disease such as MR4.5.  
The average number of ABL copies obtained with the reference method used in Napoli is 5x105 
copies/reaction, more than twice the average obtained with the other devices. This difference may 
be due to the fact that the routine method used in Napoli provides a non-calibrated ABL standard, 
which overestimates the number of ABL copies. This underlines how important is to use standards 
and controls calibrated with certified materials, in order to ensure reproducible data. 
Furthermore, RQ-BCR-ABL p210 One-Step significantly improves the quantification of the ABL 
gene compared with the routine method used in Torino. This is a very significant result because it 
was the only center that uses a One-Step method similar to our own (BCR-ABL P210 ELITe MGB 
kit, ELITech Group).  
In this type of analysis, the smaller differences are found in the comparison between RQ-BCR-ABL 
p210 One-Step and the routine method used in Bologna, obtaining a similar number of copies of 
ABL in the majority of samples. 
 
Finally, the RQ-BCR-ABL p210 One-Step device has proved to be comparable to the other three 
systems currently used in the CML therapeutic care and monitoring centers. LabNet has certified 
that ours is an easy-to-use, reproducible and robust device, which in some cases improves ABL 
quantification and is able to shorten the time of the analysis procedure. 
With the aim to minimise the variability of results, a conversion factor has been calculated and 
applied to all devices before quantifying 30 samples. Despite this, comparative data expressed in 
IS has detected the existence of main differences between different laboratories due to the method 
used.   
So far guidelines have been based on cytogenetic and molecular values taken from monitoring. 
The guidelines suggest qRT-PCR Real Time for molecular monitoring, recommending primers and 
probes design, as well as the control gene to be used. There is a lack of information about 
sensitivity, specificity and reproducibility that a device, developed for this purpose, shall have.  
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Nowadays, a variability between different assays and centers, that leads to obtain different data of 
diseases for the same patient, in accordance to the device that has been used, is still present.  
Looking at the data we can observe many differences. For example, the sample 15 has been 
classified by all the devices as MR3,i.e. the achievement of MMR. In contrast Bologna’s routine 
method obtained inferior molecular response data, reporting this patient as not reaching the MMR 
and to be submitted to further analyses, extending the uncertainty of the treatment success.  
Other differences have been noticed in samples with deeper molecular responses such as sample 
28. This sample has been detected by all the analyses as a disease’s level MR4.5. When a patient 
presents this molecular response for a prolonged period, it would be evaluated for a therapeutic 
suspension. Alternatively, the analysis made in Torino with their device has classified sample 28 as 
a MR4, that could postpone this decision to a further deeper molecular analysis.  
To avoid this kind of inconsistencies further efforts to align the results are needed, through 
standardization of design and validation of this kind of devices by guideline accepted performance.  
The current challenge in the pharmaceutical area is finding the best drug for each patient before 
the beginning of treatment, so it can target the individual towards the best therapeutic plan to avoid 
relapses and obvious consequences on the patient’s well-being and national welfare. 
The personalized medicine in CML could have great steps forward with the developing and 
marketing of ground-breaking devices such as LeukoPredict. In particular, LeukoPredict measures 
the difference in enzyme activity of BCR-ABL in patients treated with a TKI, identifying if the patient 
will respond in an optimal way or not in a few hours from the beginning of treatment. In this way, it 
could be possible to know from the very first days of diagnosis which is the best drug for a patient, 
without waiting 6 months to do a therapeutic-switch towards a different and more effective TKI. 
With this project the industrial process that implies the developing of an innovative method to have 
a prediction of therapeutic response as LeukoPredict has been analysed. In this case the term 
“industrialization” refers to an assessment of the assay’s potential as a commercial IVD device, 
since it is a project that is in the early stages of development. This project, conceived and 
developed from by University of Verona, has man points of development from an industrial 
perspective. 
The assessment of the Leukopredict’s potential as a commercial IVD device includes many 
phases, first of all the Freedom to Operate analysis that provides information about the danger of 
copyright infringement of already existing patents. This kind of analysis is also made to identify 
how patents and patent applications are spread around the world, identifying in which countries it 
would be more convenient to start a technology or dispensing business.  
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In this case we divided the research in two sections. In the first part of the analysis we identified 
potential patents or patent applications that could compromise the technology concerning the 
sample’s preparation, i.e. the enzyme BCR-ABL’s isolation keeping its tyrosine-kinase activity. In 
the second part of the analysis we evaluated the potential copyright infringements in terms of the 
sample’s analysis.  
We found a total of 16 documents that could interfere with the exit the market launch of 
LeukoPredict. We carefully analysed each of them, finding some more controversial than others. 
In the sample preparations search, the document number 1 - CN104178424 
Red blood cell lysis solution and lysis method seems to have the greatest resemblance to the 
LeukoPredict technology.  
It can be considered that the technology of LeukoPredict may infringe this patent (if granted). The 
composition of the red blood cell lysis solution used in the protocol of the technology is similar but 
not identical to the one described by the independent claim 1. The composition of the RBCs lysis 
buffer used in the technology differs for the concentration of EDTANa2, which is lower than the 
range claimed in the patent application. This patent refer to red cell lysis with the purpose to 
eliminate the fraction of red blood cells present in blood, and not with the LeukoPredict’s purpose 
of prevention of proteolysis necessary for protein detection. However, even if there is not a literal 
infringement, we consider that there is a risk of infringement by equivalence. The relevance of the 
risk of infringement by equivalence depends on the jurisdiction. The document refers to a Chinese 
patent application, in which case it would represent a limited source of risk, to the extent the 
application has not been extended abroad. 
It is with regards to the sample analysis section that more relevant documents have been found. 
We singled out 10 patent documents (not only issued patents, but also published applications) that 
could be potentially relevant. In particular, the titles number 7, 8, 9 and 12 can be considered as 
the closest prior art. As far as the title 13 (WO2007109571, US granted) is concerned, the claims 
presented in the PCT application could have been potentially relevant. Nevertheless, this 
application was filed on March 17th 2006, and therefore, it has lapsed and it cannot be infringed.  
Title 7 - US8921062 - Diagnostic and prognostic assays based on circulating tyrosine kinase 
activity it is possible that the technology infringes this patent. This is because, even though the 
method described by the independent Claim 1 is based on measuring the level of circulating 
tyrosine kinase activity in a sample of an acellular body of fluid (selected from the group consisting 
of plasma and serum), in the description of the patent it is written that the cTK activity can also be 
determined by using a cell-containing sample. Furthermore, the method includes the step of 
contacting a second sample with an effective amount of one or more BCR-ABL1 kinase inhibitors. 
This step is also included in the protocol of the LeukoPredict. Indeed, as described above, the 
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protocol includes the step of treating peripheral or bone marrow whole blood with TKIs. 
Considering this, it is possible to assert that there is a risk of infringement by equivalence. 
Title 8 - US2015184222 - Diagnostic and prognostic assays based on circulating tyrosine kinase 
activity is correlated with Title 7. The method described in Claim 1 identifies the presence or 
absence of a neoplastic disease in a subject. Our device is based on screening the inhibitory 
potential of several Bcr-Abl-targeting drugs. Considering this, as far as the Claim 1 is concerned, 
the risk of infringement is low. 
Another title that could hamper LeukoPredict’s trade is document number 9 - WO2012049329 - 
Method for predicting tyrosine kinase inhibitor resistance in patients suffering from chronic 
myelogenous leukemia. We consider that our device may infringe this patent (if granted), 
particularly as far as the independent claim 10 is concerned. Indeed, this claim (which is written to 
have a broad scope) describes a method for diagnosing CML by measuring the kinase activity and 
providing phosphorylation profiles. However, the document refers to a patent application and, 
consequently, at the moment it only represents a limited source of risk. 
As far as the independent claims 1 and 14 are concerned, it is important to point out that the 
method is based on a phosphorylation profile comprising the phosphorylation levels of 
phosphorylation sites present in at least 10 peptide markers that are listed in the table. Instead, 
LeukoPredict is based on only one kinase substrate, which is the ABL-biosensor peptide (Seq: 
CEAIYAAPFAKKK). 
The last title that is relevant to our technology is number 12 - WO2010116000 - Method for profiling 
drug compounds using protein kinase inhibitors). 
As far as the patent EP2417452 (B1) is concerned, the four independent claims describe methods 
for determining the effect of a drug on the kinase activity in a sample (claims 1 and 2) and for 
predicting the resistance of a patient to a drug (claims 3 and 4). All the methods comprise the step 
of measuring the kinase activity in a cell lysate sample in the presence and in the absence of a 
protein kinase inhibitor and the step of determining the differential phosphorylation profile. In 
particular, said protein kinase inhibitor: - Inhibits the kinase domain of a surface receptor targeted by a drug thereby mimicking the 
effect of said drug on the kinase activity in said cell lysate sample (claim 1); - Inhibits proteins associated with the signal transduction pathway of a surface receptor 
targeted by a drug thereby mimicking the effect of said drug on the drug targeted signal 
transduction pathway in said cell lysate sample (claim 2); - Acts towards proteins of one or more alternative signal transduction pathways causing 
tumor growth, thereby reporting on the activity of alternative signal transduction pathways 
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causing tumor growth which is not affected by the drug, thereby causing resistance (claim 
3); - Inhibits proteins of a signal transduction pathway not targeted by the drug, thereby 
reporting on the activity of a signal transduction pathway which is not affected by said drug, 
thereby reporting resistance (claim 4). 
As far as the patent application US2012021939 (derived from the patent application 
WO2010116000) is concerned, the four independent claims describe methods for determining the 
effect of a drug on the kinase activity in a sample (claims 1 and 2) and for predicting the resistance 
of a patient to a drug (claims 3 and 4). All the methods comprise the step of measuring the kinase 
activity in a cell lysate sample in the presence and in the absence of a protein kinase inhibitor and 
the step of determining the differential phosphorylation profile. In particular, said protein kinase 
inhibitor: - Mimics the effect of a drug on the kinase activity in the sample (claim 1); - Mimics the effect of a drug on the drug targeted signal transduction pathway in the sample 
(claim 2); - Reports on the activity of alternative signal transduction pathways causing tumor growth, 
which are not affected by the drug, thereby causing resistance (claim 3). - Reports on the activity of a signal transduction pathway which is not affected by the drug, 
thereby reporting resistance (claim 4). 
The chimeric BCR-ABL oncoprotein formed from the aberrant gene is a constitutively active 
tyrosine kinase involved in several signal transduction pathways. Considering this, it is possible to 
assert that there is an actual risk of interference between our technology and these patents.  
At a first level of analysis, it can be concluded that LeukoPredict presents a risk profile that is 
consistent with the plan to enter the market upon completion of its development and, as of the date 
of this analysis, risk are medium-to-moderate. In particular, a set of patent documents for each of 
the two aspects that characterize LeukoPredict, that might pose risks of infringement and that, at 
this stage, require increasing attention have been single out. Importantly, the identified documents 
are not necessarily yet patents. The majority refers to patent applications, which represent a limited 
source of risk. Moreover, some of these applications do not feature positive search reports and will 
be likely limited in their scope. Lastly, their geographic coverage is not yet defined and the 
correlated risk has to be assessed in relation to the expected market presence of the technology.  
For prudential reasons, a second level FTO will be done once LeukoPredict approaches the 
market and its protocol becomes definite, particularly as far as the integration of the two different 
aspects of the method is concerned. Moreover, once the preparation of the sample and the 
analysis of this are further developed, we will protect any such characteristic of its technical 
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solution that appears as distinctive and inventive and that has not been yet disclosed or made 
available to the public with patent applications. Fence patent applications would reinforce this 
device’s position on the market and allow for easier defence against potential third parties’ threats 
or claims.  
Another fundamental part of the assessment of the LeukoPredict’s potential as a commercial IVD 
device is the pharmacoeconomics study of the economic impact of this treatment on society. 
These kinds of study are requested more and more by governments to evaluate the strength and 
efficacy of a new device or health strategy in order to have all the elements to therefore include it in 
a new standard care. 
In this case we followed a decision-analytic model for the early LeukoPredict test in CML, 
integrating that in the cure for disease as a companion diagnostic.  
In particular we compared three differents strategies. In the first analysis (base-case) patients 
receive first-line treatment in line with real-world settings (33.33% per TKI, including Imatinib, 
Dasatinib and Nilotinib). In the base-case analysis, LeukoPredict led to less cost and generated 
additional life years and quality-adjusted life year during eight years and dominated standard of 
care arm. Expected differences in QALYs and LYs gained are relatively small, but should be 
expected of being considerably larger at lifetime horizon.  
On the other hand, in the scenario analysis 1, patients receive first-line treatment with Imatinib 
(100%) Imatinib. LeukoPredict to the standard treatment, in this case, is not any more cost-saving, 
but still is cost-effective bellow willingness to pay the threshold of £30,000/QALY.  
Lastly, in the scenario analysis 2, patients receive first-line treatment with Imatinib (100% Imatinib) 
but the cost of Imatinib decreases due to the generic entry that was modeled, with the prioritizing of 
patients to receive Imatinib in the first-line treatment due to the lower cost. In this case, adding 
LeukoPredict to the standard treatment lead to the even more favorable cost-effectiveness ratio of 
7371 £/QALY. 
Results demonstrated that LeukoPredict is either cost saving in the base-case analysis or very 
cost-effective, in the scenario analysis 1 – 15865 £/QALY, and in the scenario analysis 2 – 7371 
£/QALY under lower bound of the willingness to pay threshold of £30,000/QALY from the 
perspective of UK NHS over the eight years’ time horizon.  
In base-case analysis as well as in both scenario analysis LeukoPredict generated additional life 
years and quality-adjusted life year in comparison with the standard treatment. 
In conclusion, this project was able to address actual principal issues in CML. On one side hand 
we have developed and validated two devices that completely satisfy actual resquest of 
therapeutic monitoring in the pharmaceutical market making a complete panel to track CML. 
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Currently the external validation of RQ-BCR-ABL p210 One-Step made by references centers 
brought to light the need to have clinical data standardized, at least in Italy, making guidelines for 
technical characteristics of devices to obtain standardized clinical data. The development of 
devices such LeukoPredict helps to decrease the risk of disease’s progression to more aggressive 
phases, personalizing the therapy and obtaining the maximum effectiveness of therapeutical 
choices. This helps physicians in an evidence based decisional therapeutic process, avoiding 
potential conflicts of interest and providing a rationale to considering to other kinds of treatment 
when the risk of failure is too high. Finally it has been shown that this technology can be affordable 
and that could contain the cost of healthcare.  
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